STLK3
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A5A3E0 | S939 | Sugiyama | POTEF A26C1B | VALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPE |
| O95747 | S339 | Sugiyama | OXSR1 KIAA1101 OSR1 | RRVPGssGRLHKtEDGGWEWsDDEFDEEsEEGKAAIsQLRs |
| O95863 | T203 | PSP | SNAI1 SNAH | GTCGKAFSRPWLLQGHVRTHtGEKPFSCPHCSRAFADRSNL |
| P00338 | T322 | Sugiyama | LDHA PIG19 | DLVKVTLtsEEEARLKKsADtLWGIQKELQF__________ |
| P00338 | Y239 | Sugiyama | LDHA PIG19 | GtDKDKEQWKEVHKQVVEsAyEVIKLKGYtSWAIGLSVADL |
| P02786 | S151 | Sugiyama | TFRC | LsEKLDstDFTGtIKLLNENsyVPREAGsQKDENLALyVEN |
| P02786 | T336 | Sugiyama | TFRC | FNHTQFPPSRSSGLPNIPVQtISRAAAEKLFGNMEGDCPSD |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | T37 | Sugiyama | ALDOA ALDA | sDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRR |
| P04406 | Y314 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | tFDAGAGIALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsK |
| P04406 | Y320 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | GIALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsKE_____ |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P06733 | S353 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | NEKsCNCLLLKVNQIGsVTEsLQACKLAQANGWGVMVsHRs |
| P06733 | Y270 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | EFFRsGKyDLDFKsPDDPsRyIsPDQLADLyKsFIKDyPVV |
| P06733 | Y280 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | DFKsPDDPsRyIsPDQLADLyKsFIKDyPVVsIEDPFDQDD |
| P06733 | Y44 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | LFtsKGLFRAAVPsGAstGIyEALELRDNDKtRYMGKGVSK |
| P06744 | T218 | Sugiyama | GPI | QLNPESSLFIIASKTFTTQEtITNAEtAKEWFLQAAKDPSA |
| P07195 | T18 | Sugiyama | LDHB | ___MATLKEKLIAPVAEEEAtVPNNKITVVGVGQVGMACAI |
| P07237 | Y94 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | GSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFFRNGDTASPK |
| P07814 | Y827 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | EIGQNIssNssAsILESKsLyDEVAAQGEVVRKLKAEKSPK |
| P07900 | Y309 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | ELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHF |
| P07900 | Y313 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | tKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P08238 | Y301 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | ELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHF |
| P08238 | Y305 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | tKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P08238 | Y472 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | sELLRyHtsQsGDEMtsLsEyVsRMKEtQKsIyyItGEsKE |
| P09104 | Y44 | Sugiyama | ENO2 | LyTAKGLFRAAVPsGAstGIyEALELRDGDKQRYLGKGVLK |
| P09382 | T58 | Sugiyama | LGALS1 | DsNNLCLHFNPRFNAHGDANtIVCNsKDGGAWGTEQREAVF |
| P10809 | Y243 | Sugiyama | HSPD1 HSP60 | yIsPyFINtsKGQKCEFQDAyVLLsEKKIssIQsIVPALEI |
| P11142 | S40 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P11142 | T226 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | DVSILTIEDGIFEVKstAGDtHLGGEDFDNRMVNHFIAEFK |
| P11142 | T66 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | DtERLIGDAAKNQVAMNPtNtVFDAKRLIGRRFDDAVVQsD |
| P13639 | S23 | Sugiyama | EEF2 EF2 | NFtVDQIRAIMDKKANIRNMsVIAHVDHGKStLtDsLVCKA |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P13929 | Y44 | Sugiyama | ENO3 | LHtAKGRFRAAVPsGAstGIyEALELRDGDKGRYLGKGVLK |
| P14618 | T50 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | MCRLDIDsPPItARNtGIICtIGPAsRsVEtLKEMIKsGMN |
| P17066 | S42 | Sugiyama | HSPA6 HSP70B' | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P17066 | T228 | Sugiyama | HSPA6 HSP70B' | DVSVLSIDAGVFEVKAtAGDtHLGGEDFDNRLVNHFMEEFR |
| P22059 | S190 | Sugiyama | OSBP OSBP1 | QRWVTALELAKAKAVKMLAEsDEsGDEEsVsQtDKTELQNT |
| P22059 | S193 | Sugiyama | OSBP OSBP1 | VTALELAKAKAVKMLAEsDEsGDEEsVsQtDKTELQNTLRT |
| P23528 | Y140 | Sugiyama | CFL1 CFL | SKDAIKKKLtGIKHELQANCyEEVKDRCTLAEKLGGsAVIs |
| P24752 | T220 | Sugiyama | ACAT1 ACAT MAT | TAKKLNIARNEQDAyAINsytRSKAAWEAGKFGNEVIPVtV |
| P25786 | T11 | Sugiyama | PSMA1 HC2 NU PROS30 PSC2 | __________MFRNQyDNDVtVWsPQGRIHQIEYAMEAVKQ |
| P29401 | Y481 | Sugiyama | TKT | AANTKGICFIRTsRPENAIIyNNNEDFQVGQAKVVLKSKDD |
| P34931 | S42 | Sugiyama | HSPA1L | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P34931 | T228 | Sugiyama | HSPA1L | DVSILTIDDGIFEVKAtAGDtHLGGEDFDNRLVsHFVEEFK |
| P36578 | Y52 | Sugiyama | RPL4 RPL1 | IRPDIVNFVHTNLRKNNRQPyAVsELAGHQtsAEsWGtGRA |
| P37802 | T180 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | RNFsDNQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL_ |
| P38646 | T116 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | DGERLVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKD |
| P38646 | T120 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | LVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKDIKNV |
| P38646 | T398 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | SDIGEVILVGGMTRMPKVQQtVQDLFGRAPsKAVNPDEAVA |
| P38646 | Y118 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | ERLVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKDIK |
| P39019 | Y48 | Sugiyama | RPS19 | LKVPEWVDtVKLAKHKELAPyDENWFytRAAstARHLYLRG |
| P39019 | Y54 | Sugiyama | RPS19 | VDtVKLAKHKELAPyDENWFytRAAstARHLYLRGGAGVGs |
| P48741 | S42 | Sugiyama | HSPA7 HSP70B | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P48741 | T228 | Sugiyama | HSPA7 HSP70B | DVSVLSIDAGVFEVKAtAGDtHLGGEDFDNRLVNHFMEEFR |
| P49327 | S286 | Sugiyama | FASN FAS | GDIQEQLIRSLyQsAGVAPEsFEyIEAHGtGTKVGDPQELN |
| P49327 | Y277 | Sugiyama | FASN FAS | KEQGVtFPsGDIQEQLIRSLyQsAGVAPEsFEyIEAHGtGT |
| P49773 | T17 | Sugiyama | HINT1 HINT PKCI1 PRKCNH1 | ____MADEIAKAQVARPGGDtIFGKIIRKEIPAKIIFEDDR |
| P54652 | S41 | Sugiyama | HSPA2 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P54652 | T229 | Sugiyama | HSPA2 | DVSILTIEDGIFEVKstAGDtHLGGEDFDNRMVSHLAEEFK |
| P55011 | T203 | PSP | SLC12A2 NKCC1 | SSLHSGGGGGSGHHQHYYYDtHTNtYYLRtFGHNtMDAVPR |
| P55011 | T207 | PSP | SLC12A2 NKCC1 | SGGGGGSGHHQHYYYDtHTNtYYLRtFGHNtMDAVPRIDHy |
| P55011 | T212 | PSP | SLC12A2 NKCC1 | GSGHHQHYYYDtHTNtYYLRtFGHNtMDAVPRIDHyRHtAA |
| P55017 | T46 | PSP | SLC12A3 NCC TSC | LSSDEPSPPAAYDSSHPSHLtHSStFCMRtFGYNtIDVVPT |
| P55017 | T55 | SIGNOR|PSP | SLC12A3 NCC TSC | AAYDSSHPSHLtHSStFCMRtFGYNtIDVVPTYEHYANsTQ |
| P55017 | T60 | PSP | SLC12A3 NCC TSC | SHPSHLtHSStFCMRtFGYNtIDVVPTYEHYANsTQPGEPR |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60174 | T90 | Sugiyama | TPI1 TPI | VTNGAFtGEIsPGMIKDCGAtWVVLGHsERRHVFGEsDELI |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P60709 | S239 | Sugiyama | ACTB | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P60709 | S323 | Sugiyama | ACTB | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P60709 | T324 | Sugiyama | ACTB | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S148 | Sugiyama | YWHAE | YHRyLAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHP |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62280 | T15 | Sugiyama | RPS11 | ______MADIQTERAyQKQPtIFQNKKRVLLGEtGKEKLPR |
| P62736 | S241 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P62736 | S325 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P62736 | T326 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P62917 | T135 | Sugiyama | RPL8 | CLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSK |
| P62937 | Y79 | Sugiyama | PPIA CYPA | GFMCQGGDFtRHNGTGGKsIyGEKFEDENFILKHtGPGILs |
| P62942 | T7 | Sugiyama | FKBP1A FKBP1 FKBP12 | ______________MGVQVEtIsPGDGRtFPKRGQtCVVHy |
| P63220 | Y53 | Sugiyama | RPS21 | QMNVAEVDKVTGRFNGQFKtyAICGAIRRMGEsDDsILRLA |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P63261 | S239 | Sugiyama | ACTG1 ACTG | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P63261 | S323 | Sugiyama | ACTG1 ACTG | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63261 | T324 | Sugiyama | ACTG1 ACTG | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P63267 | S240 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P63267 | S324 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P63267 | T325 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68032 | S241 | Sugiyama | ACTC1 ACTC | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P68032 | S325 | Sugiyama | ACTC1 ACTC | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68032 | T326 | Sugiyama | ACTC1 ACTC | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68133 | S241 | Sugiyama | ACTA1 ACTA | VALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| P68133 | S325 | Sugiyama | ACTA1 ACTA | TTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | T326 | Sugiyama | ACTA1 ACTA | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| Q01105 | Y146 | Sugiyama | SET | tEFEDIKsGyRIDFyFDENPyFENKVLSKEFHLNEsGDPss |
| Q12792 | Y309 | Sugiyama | TWF1 PTK9 | MDVIRKIEIDNGDELtADFLyEEVHPKQHAHKQSFAKPKGP |
| Q13561 | T315 | Sugiyama | DCTN2 DCTN50 | KHKASVEDADTQSKVHQLyEtIQRWsPIASTLPELVQRLVT |
| Q13621 | S130 | SIGNOR | SLC12A1 NKCC2 | PKIEYYRNtGsIsGPKVNRPsLLEIHEQLAKNVAVTPSSAD |
| Q13621 | S91 | SIGNOR | SLC12A1 NKCC2 | DNFLQSGETAKTDASFHAYDsHTNtYYLQtFGHNtMDAVPK |
| Q13621 | T100 | SIGNOR|PSP | SLC12A1 NKCC2 | AKTDASFHAYDsHTNtYYLQtFGHNtMDAVPKIEYYRNtGs |
| Q13621 | T105 | SIGNOR|PSP | SLC12A1 NKCC2 | SFHAYDsHTNtYYLQtFGHNtMDAVPKIEYYRNtGsIsGPK |
| Q13621 | T95 | SIGNOR|PSP | SLC12A1 NKCC2 | QSGETAKTDASFHAYDsHTNtYYLQtFGHNtMDAVPKIEYY |
| Q562R1 | S240 | Sugiyama | ACTBL2 | VALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPE |
| Q6S8J3 | S939 | Sugiyama | POTEE A26C1A POTE2 | VALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPE |
| Q86W56 | Y832 | Sugiyama | PARG | DDWQRRCTEIVAIDALHFRRyLDQFVPEKMRRELNKAYCGF |
| Q96AY3 | Y201 | Sugiyama | FKBP10 FKBP65 PSEC0056 | YNGTLLDGTSFDTSYSKGGtyDtyVGsGWLIKGMDQGLLGM |
| Q96AY3 | Y204 | Sugiyama | FKBP10 FKBP65 PSEC0056 | TLLDGTSFDTSYSKGGtyDtyVGsGWLIKGMDQGLLGMCPG |
| Q9BYX7 | S239 | Sugiyama | POTEKP ACTBL3 FKSG30 | VALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPE |
| Q9H4A3 | T48 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | GSssDssVGEKLGAAAADAVtGRtEEyRRRRHtMDKDSRGA |
| Q9H4A3 | T51 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | sDssVGEKLGAAAADAVtGRtEEyRRRRHtMDKDSRGAAAt |
| Q9UBR2 | S78 | Sugiyama | CTSZ | SPADLPKSWDWRNVDGVNyAsItRNQHIPQYCGSCWAHAST |
| Q9UHW9 | S96 | SIGNOR|PSP | SLC12A6 KCC3 | DPPSDRTSHPQDVIEDLsQNsItGEHSQLLDDGHKKARNAY |
| Q9UHW9 | T1048 | PSP | SLC12A6 KCC3 | tsIGsDEDEEtETYQEKVHMtWTKDKYMASRGQKAKsMEGF |
| Q9Y3F4 | Y280 | Sugiyama | STRAP MAWD UNRIP | syKGHFGPIHCVRFSPDGELyAsGSEDGTLRLWQTVVGKty |
| Q9Y6R1 | S65 | PSP | SLC4A4 NBC NBC1 NBCE1 | HKRKtGHKEKKEKERIsENysDKsDIENADEssssILKPLI |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 1.354191e-07 | 6.868 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.848173e-07 | 6.545 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 9.722698e-07 | 6.012 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.298028e-06 | 5.887 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 4.415545e-06 | 5.355 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 4.900516e-06 | 5.310 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 4.773244e-06 | 5.321 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 4.797300e-06 | 5.319 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.557883e-05 | 4.807 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.793930e-05 | 4.746 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 2.245818e-05 | 4.649 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 4.528349e-05 | 4.344 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 4.528349e-05 | 4.344 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 4.528349e-05 | 4.344 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 4.528349e-05 | 4.344 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 6.054443e-05 | 4.218 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 7.387378e-05 | 4.132 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 8.484711e-05 | 4.071 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.144461e-04 | 3.941 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.144461e-04 | 3.941 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.144461e-04 | 3.941 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 2.023310e-04 | 3.694 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.242547e-04 | 3.649 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 2.560991e-04 | 3.592 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.665467e-04 | 3.574 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 3.318445e-04 | 3.479 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.562307e-04 | 3.448 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 3.666300e-04 | 3.436 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 3.969532e-04 | 3.401 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 4.020342e-04 | 3.396 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 4.149992e-04 | 3.382 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 4.471922e-04 | 3.350 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 4.398442e-04 | 3.357 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.648406e-04 | 3.333 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.965829e-04 | 3.304 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 5.850758e-04 | 3.233 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 8.037541e-04 | 3.095 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 8.320150e-04 | 3.080 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 8.781669e-04 | 3.056 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.015415e-03 | 2.993 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.144590e-03 | 2.941 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.224670e-03 | 2.912 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.371673e-03 | 2.863 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.472641e-03 | 2.832 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.437303e-03 | 2.842 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.585546e-03 | 2.800 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.669412e-03 | 2.777 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.677050e-03 | 2.775 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.749357e-03 | 2.757 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.095185e-03 | 2.679 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.120161e-03 | 2.674 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 2.646382e-03 | 2.577 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 2.674764e-03 | 2.573 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.734599e-03 | 2.563 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 2.880671e-03 | 2.541 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.151695e-03 | 2.501 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.151695e-03 | 2.501 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 3.662182e-03 | 2.436 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.489334e-03 | 2.457 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.662182e-03 | 2.436 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.662182e-03 | 2.436 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.600192e-03 | 2.444 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 3.715456e-03 | 2.430 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 3.917087e-03 | 2.407 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 4.263000e-03 | 2.370 | 0 | 0 |
| Kinesins | R-HSA-983189 | 4.405550e-03 | 2.356 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 4.717495e-03 | 2.326 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 5.215344e-03 | 2.283 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 5.669950e-03 | 2.246 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 5.669950e-03 | 2.246 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 5.660592e-03 | 2.247 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 5.660592e-03 | 2.247 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 5.871431e-03 | 2.231 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 6.007127e-03 | 2.221 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 6.350748e-03 | 2.197 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 7.007444e-03 | 2.154 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 7.136838e-03 | 2.146 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 7.007444e-03 | 2.154 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 8.350549e-03 | 2.078 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 8.359513e-03 | 2.078 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 8.541115e-03 | 2.068 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 9.985048e-03 | 2.001 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 9.617795e-03 | 2.017 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 9.686778e-03 | 2.014 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.056257e-02 | 1.976 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.087569e-02 | 1.964 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.141633e-02 | 1.942 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.180194e-02 | 1.928 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 1.295545e-02 | 1.888 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.307080e-02 | 1.884 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.307080e-02 | 1.884 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 1.307080e-02 | 1.884 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 1.313940e-02 | 1.881 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.469114e-02 | 1.833 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.483781e-02 | 1.829 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.404186e-02 | 1.853 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 1.522658e-02 | 1.817 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.611330e-02 | 1.793 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 1.611330e-02 | 1.793 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 1.691943e-02 | 1.772 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 1.775538e-02 | 1.751 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 1.795184e-02 | 1.746 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.848922e-02 | 1.733 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.902433e-02 | 1.721 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.230647e-02 | 1.652 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 2.247568e-02 | 1.648 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.247568e-02 | 1.648 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.247568e-02 | 1.648 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.247568e-02 | 1.648 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.247568e-02 | 1.648 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.247568e-02 | 1.648 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 2.247568e-02 | 1.648 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 2.247568e-02 | 1.648 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 2.395016e-02 | 1.621 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 2.501802e-02 | 1.602 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 2.547116e-02 | 1.594 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 2.666106e-02 | 1.574 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 2.732220e-02 | 1.563 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 2.822198e-02 | 1.549 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.843303e-02 | 1.546 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 2.843303e-02 | 1.546 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.890788e-02 | 1.539 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.261368e-02 | 1.487 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 3.218053e-02 | 1.492 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 2.954838e-02 | 1.529 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 3.185969e-02 | 1.497 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.985167e-02 | 1.525 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 3.473038e-02 | 1.459 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.473038e-02 | 1.459 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 3.473038e-02 | 1.459 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 3.473038e-02 | 1.459 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 3.473038e-02 | 1.459 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 3.605402e-02 | 1.443 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 3.605402e-02 | 1.443 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 3.625266e-02 | 1.441 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 3.625266e-02 | 1.441 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 3.625266e-02 | 1.441 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.759939e-02 | 1.425 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 4.288674e-02 | 1.368 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 4.337024e-02 | 1.363 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 4.337024e-02 | 1.363 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 4.337024e-02 | 1.363 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 4.337024e-02 | 1.363 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 3.946693e-02 | 1.404 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 4.337024e-02 | 1.363 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.898214e-02 | 1.409 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 4.212237e-02 | 1.375 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 4.337024e-02 | 1.363 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 4.445890e-02 | 1.352 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 4.445890e-02 | 1.352 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 4.479315e-02 | 1.349 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 4.479315e-02 | 1.349 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 4.667120e-02 | 1.331 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 5.399174e-02 | 1.268 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 5.399174e-02 | 1.268 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 5.399174e-02 | 1.268 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 4.977735e-02 | 1.303 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 4.977735e-02 | 1.303 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 5.116907e-02 | 1.291 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 5.466837e-02 | 1.262 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 5.453742e-02 | 1.263 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 5.399174e-02 | 1.268 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 4.898597e-02 | 1.310 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 5.477808e-02 | 1.261 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 5.478569e-02 | 1.261 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 5.539046e-02 | 1.257 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 5.539046e-02 | 1.257 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 5.539046e-02 | 1.257 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 5.595454e-02 | 1.252 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 5.666652e-02 | 1.247 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 5.809078e-02 | 1.236 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.979586e-02 | 1.223 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 7.158504e-02 | 1.145 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 7.158504e-02 | 1.145 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 7.158504e-02 | 1.145 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 7.158504e-02 | 1.145 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 7.158504e-02 | 1.145 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 7.158504e-02 | 1.145 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 7.158504e-02 | 1.145 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 7.158504e-02 | 1.145 | 0 | 0 |
| Hereditary fructose intolerance | R-HSA-5657560 | 7.158504e-02 | 1.145 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 7.158504e-02 | 1.145 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 7.158504e-02 | 1.145 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 6.378927e-02 | 1.195 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 6.378927e-02 | 1.195 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 6.378927e-02 | 1.195 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 7.412999e-02 | 1.130 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 7.412999e-02 | 1.130 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 7.412999e-02 | 1.130 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 8.063879e-02 | 1.093 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 7.392385e-02 | 1.131 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 7.392385e-02 | 1.131 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 8.330095e-02 | 1.079 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 6.346423e-02 | 1.197 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 8.421838e-02 | 1.075 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 8.363715e-02 | 1.078 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 6.725651e-02 | 1.172 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 6.378927e-02 | 1.195 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 7.412999e-02 | 1.130 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 8.063879e-02 | 1.093 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.310865e-02 | 1.136 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 6.661780e-02 | 1.176 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 6.297085e-02 | 1.201 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 7.812128e-02 | 1.107 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 7.412999e-02 | 1.130 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 6.129115e-02 | 1.213 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 7.812128e-02 | 1.107 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 6.301885e-02 | 1.201 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 7.609870e-02 | 1.119 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 7.639953e-02 | 1.117 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 8.044274e-02 | 1.095 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 7.412999e-02 | 1.130 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 8.097014e-02 | 1.092 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 6.109767e-02 | 1.214 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 8.063879e-02 | 1.093 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 6.688661e-02 | 1.175 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 8.237892e-02 | 1.084 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 7.689594e-02 | 1.114 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 8.421838e-02 | 1.075 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 8.496144e-02 | 1.071 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 8.496144e-02 | 1.071 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 8.496144e-02 | 1.071 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 8.496144e-02 | 1.071 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 1.054354e-01 | 0.977 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 1.054354e-01 | 0.977 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 1.054354e-01 | 0.977 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 1.054354e-01 | 0.977 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 1.054354e-01 | 0.977 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 1.054354e-01 | 0.977 | 0 | 0 |
| Defective SLC12A3 causes Gitelman syndrome (GS) | R-HSA-5619087 | 1.054354e-01 | 0.977 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 1.054354e-01 | 0.977 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 1.054354e-01 | 0.977 | 0 | 0 |
| XAV939 stabilizes AXIN | R-HSA-5545619 | 1.054354e-01 | 0.977 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 1.380536e-01 | 0.860 | 0 | 0 |
| Defective SLC12A1 causes Bartter syndrome 1 (BS1) | R-HSA-5619104 | 1.380536e-01 | 0.860 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 1.694844e-01 | 0.771 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 1.694844e-01 | 0.771 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.694844e-01 | 0.771 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 1.694844e-01 | 0.771 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.694844e-01 | 0.771 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 1.694844e-01 | 0.771 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 1.694844e-01 | 0.771 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 1.997708e-01 | 0.699 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 1.997708e-01 | 0.699 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 1.997708e-01 | 0.699 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.997708e-01 | 0.699 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.997708e-01 | 0.699 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 1.997708e-01 | 0.699 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 1.997708e-01 | 0.699 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 1.997708e-01 | 0.699 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 1.997708e-01 | 0.699 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 9.623423e-02 | 1.017 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 9.623423e-02 | 1.017 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 9.623423e-02 | 1.017 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 2.289546e-01 | 0.640 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 2.289546e-01 | 0.640 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.289546e-01 | 0.640 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 1.199208e-01 | 0.921 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 2.570758e-01 | 0.590 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.570758e-01 | 0.590 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 2.570758e-01 | 0.590 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 2.570758e-01 | 0.590 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 2.570758e-01 | 0.590 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.322499e-01 | 0.879 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 2.841731e-01 | 0.546 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 2.841731e-01 | 0.546 | 0 | 0 |
| Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) | R-HSA-3656244 | 2.841731e-01 | 0.546 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 2.841731e-01 | 0.546 | 0 | 0 |
| Defective ST3GAL3 causes MCT12 and EIEE15 | R-HSA-3656243 | 2.841731e-01 | 0.546 | 0 | 0 |
| Defective CHST6 causes MCDC1 | R-HSA-3656225 | 2.841731e-01 | 0.546 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 2.841731e-01 | 0.546 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.576873e-01 | 0.802 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.576873e-01 | 0.802 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 3.102836e-01 | 0.508 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 3.102836e-01 | 0.508 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 3.102836e-01 | 0.508 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.102836e-01 | 0.508 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 3.102836e-01 | 0.508 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 3.102836e-01 | 0.508 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 3.102836e-01 | 0.508 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 3.102836e-01 | 0.508 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 3.354432e-01 | 0.474 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 3.354432e-01 | 0.474 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 3.354432e-01 | 0.474 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 3.354432e-01 | 0.474 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 1.426561e-01 | 0.846 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.512920e-01 | 0.820 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.596865e-01 | 0.444 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 3.596865e-01 | 0.444 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.600894e-01 | 0.796 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.600894e-01 | 0.796 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.379032e-01 | 0.624 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 1.781270e-01 | 0.749 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.781270e-01 | 0.749 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 3.830468e-01 | 0.417 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 3.830468e-01 | 0.417 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 3.830468e-01 | 0.417 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.873465e-01 | 0.727 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.652242e-01 | 0.576 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 2.061365e-01 | 0.686 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 4.055563e-01 | 0.392 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 4.055563e-01 | 0.392 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.273757e-01 | 0.895 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.273757e-01 | 0.895 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.438865e-01 | 0.842 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.061609e-01 | 0.514 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 4.272458e-01 | 0.369 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 4.272458e-01 | 0.369 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.933536e-01 | 0.714 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 2.448464e-01 | 0.611 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 2.547045e-01 | 0.594 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.856623e-01 | 0.731 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.317576e-01 | 0.635 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 3.466471e-01 | 0.460 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.983374e-01 | 0.703 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 2.476170e-01 | 0.606 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 3.732066e-01 | 0.428 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 3.147038e-01 | 0.502 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 3.147038e-01 | 0.502 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 3.993181e-01 | 0.399 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 3.545669e-01 | 0.450 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 4.047595e-01 | 0.393 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.243887e-01 | 0.372 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 3.805351e-01 | 0.420 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.178225e-01 | 0.929 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.312269e-01 | 0.636 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 1.405875e-01 | 0.852 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.107441e-01 | 0.676 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 1.873465e-01 | 0.727 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 3.948709e-01 | 0.404 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 2.652242e-01 | 0.576 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 9.623423e-02 | 1.017 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 8.736153e-02 | 1.059 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 3.732066e-01 | 0.428 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.080467e-01 | 0.511 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 8.864476e-02 | 1.052 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 2.745753e-01 | 0.561 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 3.596865e-01 | 0.444 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 2.391604e-01 | 0.621 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 1.600894e-01 | 0.796 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.576873e-01 | 0.802 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 3.354432e-01 | 0.474 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 2.745753e-01 | 0.561 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 4.249099e-01 | 0.372 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.107441e-01 | 0.676 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 9.623423e-02 | 1.017 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 2.289546e-01 | 0.640 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 2.379032e-01 | 0.624 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 3.603587e-01 | 0.443 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.022667e-01 | 0.990 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.426561e-01 | 0.846 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.189988e-01 | 0.924 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 1.997708e-01 | 0.699 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 1.341922e-01 | 0.872 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 3.596865e-01 | 0.444 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.785932e-01 | 0.748 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.093328e-01 | 0.961 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 3.993181e-01 | 0.399 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 3.993181e-01 | 0.399 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 1.099376e-01 | 0.959 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 2.501564e-01 | 0.602 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 2.448464e-01 | 0.611 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.099376e-01 | 0.959 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 1.187765e-01 | 0.925 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.902874e-01 | 0.409 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 2.289546e-01 | 0.640 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 3.102836e-01 | 0.508 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 4.272458e-01 | 0.369 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.309729e-01 | 0.883 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 3.197260e-01 | 0.495 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 4.146003e-01 | 0.382 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.707256e-01 | 0.768 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.357399e-01 | 0.867 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.277157e-01 | 0.485 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.178225e-01 | 0.929 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 2.841731e-01 | 0.546 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.690379e-01 | 0.772 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 3.332258e-01 | 0.477 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 2.396566e-01 | 0.620 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.756361e-01 | 0.755 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 4.209743e-01 | 0.376 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 2.556339e-01 | 0.592 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 1.448508e-01 | 0.839 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 9.256998e-02 | 1.034 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.646170e-01 | 0.577 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.966864e-01 | 0.706 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.572198e-01 | 0.803 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 1.199208e-01 | 0.921 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 2.925450e-01 | 0.534 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 3.667673e-01 | 0.436 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 2.061365e-01 | 0.686 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 3.295602e-01 | 0.482 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.377978e-01 | 0.471 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 1.054354e-01 | 0.977 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.380536e-01 | 0.860 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.997708e-01 | 0.699 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 9.623423e-02 | 1.017 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 2.289546e-01 | 0.640 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.079019e-01 | 0.967 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.079019e-01 | 0.967 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.079019e-01 | 0.967 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 2.570758e-01 | 0.590 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 2.570758e-01 | 0.590 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 2.570758e-01 | 0.590 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.322499e-01 | 0.879 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 1.707256e-01 | 0.768 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 3.354432e-01 | 0.474 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 2.107441e-01 | 0.676 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.512920e-01 | 0.820 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 3.596865e-01 | 0.444 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 2.515542e-01 | 0.599 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 3.830468e-01 | 0.417 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.253286e-01 | 0.647 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 4.272458e-01 | 0.369 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 4.272458e-01 | 0.369 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 3.599778e-01 | 0.444 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 3.147038e-01 | 0.502 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 3.348384e-01 | 0.475 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.655344e-01 | 0.576 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.441631e-01 | 0.463 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 3.053199e-01 | 0.515 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 2.107441e-01 | 0.676 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 3.147038e-01 | 0.502 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.799762e-01 | 0.553 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 2.925450e-01 | 0.534 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.397473e-01 | 0.620 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 8.760732e-02 | 1.057 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 2.239247e-01 | 0.650 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 2.637026e-01 | 0.579 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 2.799762e-01 | 0.553 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 2.289546e-01 | 0.640 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.379032e-01 | 0.624 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.448464e-01 | 0.611 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.881720e-01 | 0.540 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 2.635747e-01 | 0.579 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 2.379032e-01 | 0.624 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.820868e-01 | 0.740 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.667847e-01 | 0.778 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 1.997708e-01 | 0.699 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 2.289546e-01 | 0.640 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 1.576873e-01 | 0.802 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 3.102836e-01 | 0.508 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.102836e-01 | 0.508 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 3.354432e-01 | 0.474 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 3.596865e-01 | 0.444 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 3.596865e-01 | 0.444 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 1.873465e-01 | 0.727 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 2.788939e-01 | 0.555 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.580339e-01 | 0.588 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 1.899384e-01 | 0.721 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.400010e-01 | 0.854 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.273757e-01 | 0.895 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 3.354432e-01 | 0.474 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.572198e-01 | 0.803 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 3.798475e-01 | 0.420 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.414953e-02 | 1.026 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 2.448464e-01 | 0.611 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.338903e-01 | 0.873 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 4.020055e-01 | 0.396 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.707256e-01 | 0.768 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 2.788939e-01 | 0.555 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 3.332258e-01 | 0.477 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 3.948709e-01 | 0.404 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 3.406595e-01 | 0.468 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 1.178225e-01 | 0.929 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.983374e-01 | 0.703 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 3.005240e-01 | 0.522 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 2.731089e-01 | 0.564 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 3.296669e-01 | 0.482 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 3.462265e-01 | 0.461 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 1.012447e-01 | 0.995 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 1.694844e-01 | 0.771 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 1.997708e-01 | 0.699 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 2.289546e-01 | 0.640 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 1.079019e-01 | 0.967 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 2.570758e-01 | 0.590 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 2.570758e-01 | 0.590 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 1.448508e-01 | 0.839 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 3.354432e-01 | 0.474 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 3.354432e-01 | 0.474 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 9.414953e-02 | 1.026 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 3.830468e-01 | 0.417 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 3.061609e-01 | 0.514 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 4.272458e-01 | 0.369 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 4.272458e-01 | 0.369 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 2.646170e-01 | 0.577 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 3.332258e-01 | 0.477 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 2.396566e-01 | 0.620 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 2.396566e-01 | 0.620 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 3.863231e-01 | 0.413 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.202570e-01 | 0.920 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 4.121830e-01 | 0.385 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.103713e-01 | 0.508 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.555996e-01 | 0.808 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.368829e-01 | 0.864 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 9.650925e-02 | 1.015 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 2.532735e-01 | 0.596 | 0 | 0 |
| S Phase | R-HSA-69242 | 4.202463e-01 | 0.376 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.261524e-01 | 0.899 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 1.099376e-01 | 0.959 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 1.083958e-01 | 0.965 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.515542e-01 | 0.599 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 3.332258e-01 | 0.477 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 1.177078e-01 | 0.929 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 2.161630e-01 | 0.665 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 4.207784e-01 | 0.376 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 4.207784e-01 | 0.376 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 4.052340e-01 | 0.392 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 1.259108e-01 | 0.900 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.242924e-01 | 0.649 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 2.515542e-01 | 0.599 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.966864e-01 | 0.706 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 2.945963e-01 | 0.531 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.732066e-01 | 0.428 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 4.095993e-01 | 0.388 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 1.781270e-01 | 0.749 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.817559e-01 | 0.741 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 4.249099e-01 | 0.372 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 1.438503e-01 | 0.842 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 2.788939e-01 | 0.555 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.476170e-01 | 0.606 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 4.121830e-01 | 0.385 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 4.127367e-01 | 0.384 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.048370e-01 | 0.979 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 1.997708e-01 | 0.699 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 1.997708e-01 | 0.699 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 9.623423e-02 | 1.017 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 2.289546e-01 | 0.640 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.079019e-01 | 0.967 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.079019e-01 | 0.967 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 2.570758e-01 | 0.590 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 3.102836e-01 | 0.508 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 1.839339e-01 | 0.735 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 3.354432e-01 | 0.474 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 9.256998e-02 | 1.034 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 2.515542e-01 | 0.599 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 3.830468e-01 | 0.417 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 2.652242e-01 | 0.576 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.055563e-01 | 0.392 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.925450e-01 | 0.534 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 3.061609e-01 | 0.514 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 2.547045e-01 | 0.594 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 2.547045e-01 | 0.594 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.230609e-01 | 0.910 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 2.646170e-01 | 0.577 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.187765e-01 | 0.925 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 3.466471e-01 | 0.460 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.556339e-01 | 0.592 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.993181e-01 | 0.399 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 3.046586e-01 | 0.516 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 3.462265e-01 | 0.461 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 3.659769e-01 | 0.437 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.357399e-01 | 0.867 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 3.961906e-01 | 0.402 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.108471e-01 | 0.386 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 2.156871e-01 | 0.666 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 3.842936e-01 | 0.415 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 3.013182e-01 | 0.521 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 8.932307e-02 | 1.049 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 3.596865e-01 | 0.444 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 2.652242e-01 | 0.576 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 2.788939e-01 | 0.555 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 4.272458e-01 | 0.369 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 3.197260e-01 | 0.495 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 3.599778e-01 | 0.444 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.891772e-01 | 0.723 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 9.953229e-02 | 1.002 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 2.774760e-01 | 0.557 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 2.514480e-01 | 0.600 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.672378e-01 | 0.777 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 8.801941e-02 | 1.055 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.572198e-01 | 0.803 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 3.299691e-01 | 0.482 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.854939e-01 | 0.414 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.199208e-01 | 0.921 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.570758e-01 | 0.590 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 2.841731e-01 | 0.546 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 9.481991e-02 | 1.023 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 3.354432e-01 | 0.474 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.596865e-01 | 0.444 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 4.055563e-01 | 0.392 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.350514e-01 | 0.629 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 2.448464e-01 | 0.611 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.247713e-01 | 0.488 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 3.046586e-01 | 0.516 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 8.760732e-02 | 1.057 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 3.046430e-01 | 0.516 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.100274e-01 | 0.678 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 4.121830e-01 | 0.385 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 4.060125e-01 | 0.391 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 3.348384e-01 | 0.475 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 3.448984e-01 | 0.462 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.127367e-01 | 0.384 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.691754e-01 | 0.772 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 2.580339e-01 | 0.588 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 3.148135e-01 | 0.502 | 0 | 0 |
| Immune System | R-HSA-168256 | 3.380073e-01 | 0.471 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 3.596865e-01 | 0.444 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 3.596865e-01 | 0.444 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 9.720538e-02 | 1.012 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 3.732066e-01 | 0.428 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 2.102161e-01 | 0.677 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 3.543922e-01 | 0.451 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 1.448508e-01 | 0.839 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 1.099376e-01 | 0.959 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.239630e-01 | 0.907 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 3.993181e-01 | 0.399 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 2.637026e-01 | 0.579 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 2.289546e-01 | 0.640 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 1.199208e-01 | 0.921 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 3.596865e-01 | 0.444 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.781270e-01 | 0.749 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 3.830468e-01 | 0.417 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 4.272458e-01 | 0.369 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.919626e-01 | 0.717 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.056283e-01 | 0.976 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.123517e-01 | 0.949 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.444837e-01 | 0.612 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 2.925450e-01 | 0.534 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 3.849398e-01 | 0.415 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 3.732066e-01 | 0.428 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 3.863231e-01 | 0.413 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 3.805351e-01 | 0.420 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 3.805351e-01 | 0.420 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 3.805351e-01 | 0.420 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 3.102836e-01 | 0.508 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 2.107441e-01 | 0.676 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.156871e-01 | 0.666 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.732066e-01 | 0.428 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 3.732066e-01 | 0.428 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.945963e-01 | 0.531 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 3.466471e-01 | 0.460 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 3.046430e-01 | 0.516 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 3.046430e-01 | 0.516 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 2.799762e-01 | 0.553 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.147038e-01 | 0.502 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 9.481991e-02 | 1.023 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.839339e-01 | 0.735 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.107441e-01 | 0.676 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 4.249099e-01 | 0.372 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 2.533048e-01 | 0.596 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 9.986451e-02 | 1.001 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 9.481991e-02 | 1.023 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 3.448984e-01 | 0.462 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 1.972827e-01 | 0.705 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.243887e-01 | 0.372 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 4.062722e-01 | 0.391 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 2.652242e-01 | 0.576 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.107441e-01 | 0.676 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 3.430982e-01 | 0.465 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 3.332258e-01 | 0.477 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 8.570562e-02 | 1.067 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 3.830468e-01 | 0.417 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 1.311294e-01 | 0.882 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.448508e-01 | 0.839 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 3.712432e-01 | 0.430 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 3.863231e-01 | 0.413 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 3.466471e-01 | 0.460 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 4.055563e-01 | 0.392 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 3.466471e-01 | 0.460 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 3.061609e-01 | 0.514 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.417980e-01 | 0.848 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 4.291840e-01 | 0.367 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 4.321999e-01 | 0.364 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 4.332172e-01 | 0.363 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.341200e-01 | 0.362 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 4.374918e-01 | 0.359 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 4.374918e-01 | 0.359 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 4.381650e-01 | 0.358 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 4.384689e-01 | 0.358 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 4.437380e-01 | 0.353 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 4.437899e-01 | 0.353 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 4.455081e-01 | 0.351 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 4.456394e-01 | 0.351 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 4.481452e-01 | 0.349 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 4.481452e-01 | 0.349 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 4.481452e-01 | 0.349 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 4.481452e-01 | 0.349 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 4.481452e-01 | 0.349 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 4.481452e-01 | 0.349 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 4.481452e-01 | 0.349 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 4.481452e-01 | 0.349 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 4.481452e-01 | 0.349 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 4.481452e-01 | 0.349 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 4.481452e-01 | 0.349 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.481452e-01 | 0.349 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 4.481452e-01 | 0.349 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 4.481452e-01 | 0.349 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 4.481452e-01 | 0.349 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 4.481452e-01 | 0.349 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 4.481452e-01 | 0.349 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 4.481452e-01 | 0.349 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 4.499224e-01 | 0.347 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 4.499224e-01 | 0.347 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 4.499224e-01 | 0.347 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 4.499224e-01 | 0.347 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 4.503413e-01 | 0.346 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 4.521204e-01 | 0.345 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 4.533943e-01 | 0.344 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 4.533943e-01 | 0.344 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 4.599098e-01 | 0.337 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 4.599098e-01 | 0.337 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 4.621960e-01 | 0.335 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 4.621960e-01 | 0.335 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 4.621960e-01 | 0.335 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.621960e-01 | 0.335 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.621960e-01 | 0.335 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 4.621960e-01 | 0.335 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 4.670057e-01 | 0.331 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 4.682833e-01 | 0.329 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 4.682833e-01 | 0.329 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 4.682833e-01 | 0.329 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 4.682833e-01 | 0.329 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 4.682833e-01 | 0.329 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 4.682833e-01 | 0.329 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 4.682833e-01 | 0.329 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 4.682833e-01 | 0.329 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 4.682833e-01 | 0.329 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 4.697141e-01 | 0.328 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 4.723913e-01 | 0.326 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 4.723913e-01 | 0.326 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 4.723913e-01 | 0.326 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 4.737145e-01 | 0.324 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 4.740730e-01 | 0.324 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 4.740730e-01 | 0.324 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 4.740730e-01 | 0.324 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 4.743074e-01 | 0.324 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 4.743074e-01 | 0.324 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 4.795881e-01 | 0.319 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 4.817767e-01 | 0.317 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 4.862523e-01 | 0.313 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 4.862523e-01 | 0.313 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 4.862523e-01 | 0.313 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 4.876876e-01 | 0.312 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 4.876876e-01 | 0.312 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 4.876876e-01 | 0.312 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 4.876876e-01 | 0.312 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 4.876876e-01 | 0.312 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 4.876876e-01 | 0.312 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 4.950852e-01 | 0.305 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.003050e-01 | 0.301 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 5.025053e-01 | 0.299 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 5.025053e-01 | 0.299 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 5.063850e-01 | 0.296 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 5.063850e-01 | 0.296 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 5.063850e-01 | 0.296 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 5.063850e-01 | 0.296 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 5.063850e-01 | 0.296 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 5.063850e-01 | 0.296 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 5.063850e-01 | 0.296 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 5.063850e-01 | 0.296 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 5.063850e-01 | 0.296 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 5.063850e-01 | 0.296 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 5.063850e-01 | 0.296 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 5.063850e-01 | 0.296 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 5.089183e-01 | 0.293 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 5.091431e-01 | 0.293 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 5.096268e-01 | 0.293 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 5.096268e-01 | 0.293 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 5.157777e-01 | 0.288 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 5.157777e-01 | 0.288 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.184908e-01 | 0.285 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 5.210500e-01 | 0.283 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 5.210500e-01 | 0.283 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 5.210500e-01 | 0.283 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 5.210500e-01 | 0.283 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 5.237032e-01 | 0.281 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 5.244011e-01 | 0.280 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 5.244011e-01 | 0.280 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 5.244011e-01 | 0.280 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 5.244011e-01 | 0.280 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 5.244011e-01 | 0.280 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 5.244011e-01 | 0.280 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 5.244011e-01 | 0.280 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 5.244011e-01 | 0.280 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.322937e-01 | 0.274 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 5.322937e-01 | 0.274 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 5.322937e-01 | 0.274 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 5.322937e-01 | 0.274 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 5.352564e-01 | 0.271 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 5.417607e-01 | 0.266 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 5.417607e-01 | 0.266 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 5.417607e-01 | 0.266 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 5.417607e-01 | 0.266 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 5.417607e-01 | 0.266 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 5.417607e-01 | 0.266 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 5.417607e-01 | 0.266 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 5.433558e-01 | 0.265 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 5.433558e-01 | 0.265 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 5.433558e-01 | 0.265 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 5.433558e-01 | 0.265 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 5.433558e-01 | 0.265 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 5.450826e-01 | 0.264 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 5.456821e-01 | 0.263 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 5.494446e-01 | 0.260 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 5.494446e-01 | 0.260 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 5.511548e-01 | 0.259 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 5.537547e-01 | 0.257 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 5.542345e-01 | 0.256 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 5.542345e-01 | 0.256 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 5.542345e-01 | 0.256 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 5.584876e-01 | 0.253 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 5.584876e-01 | 0.253 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 5.584876e-01 | 0.253 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 5.584876e-01 | 0.253 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 5.584876e-01 | 0.253 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 5.584876e-01 | 0.253 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 5.584876e-01 | 0.253 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 5.623277e-01 | 0.250 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 5.625931e-01 | 0.250 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 5.631882e-01 | 0.249 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 5.649284e-01 | 0.248 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.680289e-01 | 0.246 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 5.690945e-01 | 0.245 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 5.690945e-01 | 0.245 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 5.692766e-01 | 0.245 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 5.695954e-01 | 0.244 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 5.708001e-01 | 0.244 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 5.708001e-01 | 0.244 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 5.746050e-01 | 0.241 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 5.746050e-01 | 0.241 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 5.746050e-01 | 0.241 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 5.746050e-01 | 0.241 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 5.754367e-01 | 0.240 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 5.754367e-01 | 0.240 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 5.754367e-01 | 0.240 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 5.754367e-01 | 0.240 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 5.754367e-01 | 0.240 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 5.765025e-01 | 0.239 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 5.766799e-01 | 0.239 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 5.791703e-01 | 0.237 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 5.817394e-01 | 0.235 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 5.857585e-01 | 0.232 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 5.857585e-01 | 0.232 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 5.871214e-01 | 0.231 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 5.874370e-01 | 0.231 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 5.874370e-01 | 0.231 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 5.888046e-01 | 0.230 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 5.901350e-01 | 0.229 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 5.901350e-01 | 0.229 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 5.901350e-01 | 0.229 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 5.901350e-01 | 0.229 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 5.901350e-01 | 0.229 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 5.901350e-01 | 0.229 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 5.901350e-01 | 0.229 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 5.901350e-01 | 0.229 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 5.901350e-01 | 0.229 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 5.955989e-01 | 0.225 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 5.958936e-01 | 0.225 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 5.958936e-01 | 0.225 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 5.958936e-01 | 0.225 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 5.977607e-01 | 0.223 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 6.050989e-01 | 0.218 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 6.050989e-01 | 0.218 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 6.050989e-01 | 0.218 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 6.050989e-01 | 0.218 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 6.050989e-01 | 0.218 | 0 | 0 |
| Keratan sulfate degradation | R-HSA-2022857 | 6.050989e-01 | 0.218 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 6.050989e-01 | 0.218 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 6.050989e-01 | 0.218 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 6.050989e-01 | 0.218 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 6.058417e-01 | 0.218 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 6.070182e-01 | 0.217 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 6.117764e-01 | 0.213 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 6.194466e-01 | 0.208 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 6.194466e-01 | 0.208 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 6.195173e-01 | 0.208 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 6.195173e-01 | 0.208 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 6.195173e-01 | 0.208 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 6.195173e-01 | 0.208 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 6.195173e-01 | 0.208 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 6.195173e-01 | 0.208 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 6.195173e-01 | 0.208 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 6.195173e-01 | 0.208 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 6.221612e-01 | 0.206 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 6.251779e-01 | 0.204 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 6.251779e-01 | 0.204 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.272627e-01 | 0.203 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 6.334102e-01 | 0.198 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 6.334102e-01 | 0.198 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 6.334102e-01 | 0.198 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 6.334102e-01 | 0.198 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 6.334102e-01 | 0.198 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 6.334102e-01 | 0.198 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 6.345669e-01 | 0.198 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 6.345669e-01 | 0.198 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 6.354080e-01 | 0.197 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.371096e-01 | 0.196 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 6.423213e-01 | 0.192 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 6.427329e-01 | 0.192 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 6.437710e-01 | 0.191 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 6.467966e-01 | 0.189 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 6.467966e-01 | 0.189 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 6.467966e-01 | 0.189 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 6.467966e-01 | 0.189 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 6.467966e-01 | 0.189 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 6.527910e-01 | 0.185 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 6.527910e-01 | 0.185 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 6.527910e-01 | 0.185 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 6.532667e-01 | 0.185 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.570242e-01 | 0.182 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 6.596950e-01 | 0.181 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 6.596950e-01 | 0.181 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 6.596950e-01 | 0.181 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 6.596950e-01 | 0.181 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 6.616282e-01 | 0.179 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 6.642108e-01 | 0.178 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 6.656905e-01 | 0.177 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 6.702838e-01 | 0.174 | 0 | 0 |
| CYP2E1 reactions | R-HSA-211999 | 6.721231e-01 | 0.173 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 6.721231e-01 | 0.173 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 6.721231e-01 | 0.173 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 6.721231e-01 | 0.173 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 6.721231e-01 | 0.173 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 6.760948e-01 | 0.170 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 6.760948e-01 | 0.170 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 6.787593e-01 | 0.168 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 6.787593e-01 | 0.168 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 6.821193e-01 | 0.166 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 6.840981e-01 | 0.165 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 6.840981e-01 | 0.165 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 6.840981e-01 | 0.165 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 6.840981e-01 | 0.165 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 6.840981e-01 | 0.165 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 6.840981e-01 | 0.165 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 6.840981e-01 | 0.165 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 6.840981e-01 | 0.165 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 6.840981e-01 | 0.165 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 6.840981e-01 | 0.165 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 6.840981e-01 | 0.165 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 6.840981e-01 | 0.165 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 6.870563e-01 | 0.163 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 6.870563e-01 | 0.163 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 6.870563e-01 | 0.163 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 6.951766e-01 | 0.158 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 6.956364e-01 | 0.158 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 6.956364e-01 | 0.158 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 6.956364e-01 | 0.158 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 6.956364e-01 | 0.158 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 6.956364e-01 | 0.158 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 6.956364e-01 | 0.158 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 6.966438e-01 | 0.157 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 6.981004e-01 | 0.156 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 7.031220e-01 | 0.153 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 7.067540e-01 | 0.151 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 7.067540e-01 | 0.151 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 7.067540e-01 | 0.151 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 7.067540e-01 | 0.151 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 7.067540e-01 | 0.151 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 7.067540e-01 | 0.151 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 7.067540e-01 | 0.151 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 7.067540e-01 | 0.151 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 7.108944e-01 | 0.148 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 7.108944e-01 | 0.148 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 7.114453e-01 | 0.148 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 7.114453e-01 | 0.148 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 7.127982e-01 | 0.147 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.166086e-01 | 0.145 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 7.173165e-01 | 0.144 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 7.174661e-01 | 0.144 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 7.174661e-01 | 0.144 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.174661e-01 | 0.144 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 7.174661e-01 | 0.144 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 7.174661e-01 | 0.144 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 7.174661e-01 | 0.144 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 7.174661e-01 | 0.144 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 7.200316e-01 | 0.143 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.217274e-01 | 0.142 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 7.259284e-01 | 0.139 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 7.259284e-01 | 0.139 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 7.274742e-01 | 0.138 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 7.277875e-01 | 0.138 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 7.277875e-01 | 0.138 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 7.277875e-01 | 0.138 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 7.277875e-01 | 0.138 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 7.277875e-01 | 0.138 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 7.277875e-01 | 0.138 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.277875e-01 | 0.138 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 7.331943e-01 | 0.135 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 7.331943e-01 | 0.135 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 7.331943e-01 | 0.135 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 7.377325e-01 | 0.132 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 7.377325e-01 | 0.132 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 7.377325e-01 | 0.132 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 7.377325e-01 | 0.132 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 7.377325e-01 | 0.132 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 7.377325e-01 | 0.132 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 7.377325e-01 | 0.132 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.377325e-01 | 0.132 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 7.377859e-01 | 0.132 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 7.472353e-01 | 0.127 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 7.473148e-01 | 0.126 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 7.473148e-01 | 0.126 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 7.473148e-01 | 0.126 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 7.473148e-01 | 0.126 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.477193e-01 | 0.126 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.482670e-01 | 0.126 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 7.494416e-01 | 0.125 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 7.532714e-01 | 0.123 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 7.541361e-01 | 0.123 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 7.565475e-01 | 0.121 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 7.565475e-01 | 0.121 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 7.565475e-01 | 0.121 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 7.589709e-01 | 0.120 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 7.644430e-01 | 0.117 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 7.654434e-01 | 0.116 | 0 | 0 |
| Keratan sulfate biosynthesis | R-HSA-2022854 | 7.654434e-01 | 0.116 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 7.654434e-01 | 0.116 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 7.654434e-01 | 0.116 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 7.654434e-01 | 0.116 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 7.654434e-01 | 0.116 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 7.654434e-01 | 0.116 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 7.654434e-01 | 0.116 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 7.654434e-01 | 0.116 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 7.654434e-01 | 0.116 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 7.654434e-01 | 0.116 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 7.671048e-01 | 0.115 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 7.734199e-01 | 0.112 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 7.740147e-01 | 0.111 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 7.740147e-01 | 0.111 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 7.740147e-01 | 0.111 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 7.740147e-01 | 0.111 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 7.740147e-01 | 0.111 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 7.740147e-01 | 0.111 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 7.740147e-01 | 0.111 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 7.750844e-01 | 0.111 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 7.802556e-01 | 0.108 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 7.822734e-01 | 0.107 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 7.822734e-01 | 0.107 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 7.822734e-01 | 0.107 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 7.822734e-01 | 0.107 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 7.822734e-01 | 0.107 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 7.822734e-01 | 0.107 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 7.822734e-01 | 0.107 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 7.822734e-01 | 0.107 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 7.822734e-01 | 0.107 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 7.856027e-01 | 0.105 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 7.856027e-01 | 0.105 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 7.902307e-01 | 0.102 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 7.902307e-01 | 0.102 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 7.902307e-01 | 0.102 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 7.902307e-01 | 0.102 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 7.914755e-01 | 0.102 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 7.914755e-01 | 0.102 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 7.914755e-01 | 0.102 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 7.914755e-01 | 0.102 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 7.914755e-01 | 0.102 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 7.914755e-01 | 0.102 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.972059e-01 | 0.098 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 7.972059e-01 | 0.098 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 7.972059e-01 | 0.098 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 7.978977e-01 | 0.098 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 7.978977e-01 | 0.098 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 7.978977e-01 | 0.098 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 7.978977e-01 | 0.098 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 7.978977e-01 | 0.098 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 7.978977e-01 | 0.098 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 7.983622e-01 | 0.098 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.991675e-01 | 0.097 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 8.027966e-01 | 0.095 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 8.027966e-01 | 0.095 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 8.027966e-01 | 0.095 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 8.052849e-01 | 0.094 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.052849e-01 | 0.094 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 8.052849e-01 | 0.094 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 8.052849e-01 | 0.094 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 8.052849e-01 | 0.094 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 8.052849e-01 | 0.094 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 8.082501e-01 | 0.092 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 8.092567e-01 | 0.092 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 8.124025e-01 | 0.090 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 8.124025e-01 | 0.090 | 0 | 0 |
| Depurination | R-HSA-73927 | 8.124025e-01 | 0.090 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 8.124025e-01 | 0.090 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 8.124025e-01 | 0.090 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 8.124025e-01 | 0.090 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 8.135688e-01 | 0.090 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 8.137630e-01 | 0.090 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 8.137691e-01 | 0.089 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 8.181788e-01 | 0.087 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 8.181788e-01 | 0.087 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 8.187555e-01 | 0.087 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 8.192604e-01 | 0.087 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.192604e-01 | 0.087 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 8.192604e-01 | 0.087 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 8.192604e-01 | 0.087 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 8.225053e-01 | 0.085 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 8.225053e-01 | 0.085 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.225053e-01 | 0.085 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 8.238125e-01 | 0.084 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.245963e-01 | 0.084 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 8.258679e-01 | 0.083 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 8.258679e-01 | 0.083 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 8.258679e-01 | 0.083 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 8.258679e-01 | 0.083 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 8.258679e-01 | 0.083 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 8.258679e-01 | 0.083 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 8.258679e-01 | 0.083 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 8.258679e-01 | 0.083 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 8.258679e-01 | 0.083 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 8.287426e-01 | 0.082 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 8.287426e-01 | 0.082 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 8.287426e-01 | 0.082 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 8.322343e-01 | 0.080 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 8.322343e-01 | 0.080 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 8.322343e-01 | 0.080 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 8.322343e-01 | 0.080 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 8.322343e-01 | 0.080 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 8.369355e-01 | 0.077 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 8.382316e-01 | 0.077 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 8.383683e-01 | 0.077 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 8.383683e-01 | 0.077 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 8.383683e-01 | 0.077 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 8.383683e-01 | 0.077 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 8.389432e-01 | 0.076 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 8.440757e-01 | 0.074 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 8.442784e-01 | 0.074 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 8.442784e-01 | 0.074 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 8.442784e-01 | 0.074 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 8.442784e-01 | 0.074 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 8.442784e-01 | 0.074 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 8.499727e-01 | 0.071 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 8.499727e-01 | 0.071 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 8.499727e-01 | 0.071 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 8.499727e-01 | 0.071 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 8.515748e-01 | 0.070 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 8.554592e-01 | 0.068 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 8.554592e-01 | 0.068 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 8.554592e-01 | 0.068 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 8.576289e-01 | 0.067 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 8.607453e-01 | 0.065 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 8.607453e-01 | 0.065 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 8.607453e-01 | 0.065 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 8.607453e-01 | 0.065 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 8.607453e-01 | 0.065 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 8.607453e-01 | 0.065 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 8.607453e-01 | 0.065 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 8.607453e-01 | 0.065 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 8.611302e-01 | 0.065 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 8.611302e-01 | 0.065 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 8.639083e-01 | 0.064 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 8.658384e-01 | 0.063 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 8.658384e-01 | 0.063 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 8.658384e-01 | 0.063 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 8.658384e-01 | 0.063 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.658384e-01 | 0.063 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.658384e-01 | 0.063 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 8.658384e-01 | 0.063 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 8.678063e-01 | 0.062 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 8.707456e-01 | 0.060 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 8.707456e-01 | 0.060 | 0 | 0 |
| Keratan sulfate/keratin metabolism | R-HSA-1638074 | 8.800288e-01 | 0.056 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 8.800288e-01 | 0.056 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 8.800288e-01 | 0.056 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 8.814875e-01 | 0.055 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 8.823938e-01 | 0.054 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 8.886463e-01 | 0.051 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 8.886463e-01 | 0.051 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 8.886463e-01 | 0.051 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 8.886463e-01 | 0.051 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 8.893792e-01 | 0.051 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 8.898093e-01 | 0.051 | 0 | 0 |
| Disease | R-HSA-1643685 | 8.918589e-01 | 0.050 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 8.921806e-01 | 0.050 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 8.923422e-01 | 0.049 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 8.927205e-01 | 0.049 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 8.927205e-01 | 0.049 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 8.927205e-01 | 0.049 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 8.927205e-01 | 0.049 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 8.954809e-01 | 0.048 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 8.966458e-01 | 0.047 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.966458e-01 | 0.047 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 8.966458e-01 | 0.047 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 8.968079e-01 | 0.047 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 8.985343e-01 | 0.046 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.004278e-01 | 0.046 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.027537e-01 | 0.044 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.040715e-01 | 0.044 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 9.040715e-01 | 0.044 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 9.043935e-01 | 0.044 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.072032e-01 | 0.042 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 9.075822e-01 | 0.042 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.075822e-01 | 0.042 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 9.075822e-01 | 0.042 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.092290e-01 | 0.041 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 9.099090e-01 | 0.041 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 9.100577e-01 | 0.041 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.123800e-01 | 0.040 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.142233e-01 | 0.039 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 9.151757e-01 | 0.038 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.152883e-01 | 0.038 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.203880e-01 | 0.036 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.203880e-01 | 0.036 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.203880e-01 | 0.036 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 9.233024e-01 | 0.035 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.233024e-01 | 0.035 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.252052e-01 | 0.034 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.261103e-01 | 0.033 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 9.261103e-01 | 0.033 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 9.271676e-01 | 0.033 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 9.288156e-01 | 0.032 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 9.288156e-01 | 0.032 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 9.292297e-01 | 0.032 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 9.292297e-01 | 0.032 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.292297e-01 | 0.032 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 9.305763e-01 | 0.031 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.309516e-01 | 0.031 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.309516e-01 | 0.031 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.309516e-01 | 0.031 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.316252e-01 | 0.031 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.339331e-01 | 0.030 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 9.341050e-01 | 0.030 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.342639e-01 | 0.030 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 9.360124e-01 | 0.029 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.373451e-01 | 0.028 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.386832e-01 | 0.027 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 9.392316e-01 | 0.027 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 9.396626e-01 | 0.027 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 9.400666e-01 | 0.027 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 9.409288e-01 | 0.026 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 9.409288e-01 | 0.026 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.428442e-01 | 0.026 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 9.451768e-01 | 0.024 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.471849e-01 | 0.024 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.471849e-01 | 0.024 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.471849e-01 | 0.024 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 9.487172e-01 | 0.023 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.514509e-01 | 0.022 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 9.514509e-01 | 0.022 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.524961e-01 | 0.021 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.524961e-01 | 0.021 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 9.527662e-01 | 0.021 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.527795e-01 | 0.021 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.545096e-01 | 0.020 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.545096e-01 | 0.020 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 9.552976e-01 | 0.020 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 9.561764e-01 | 0.019 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.577823e-01 | 0.019 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.593294e-01 | 0.018 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.608199e-01 | 0.017 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.614629e-01 | 0.017 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.636393e-01 | 0.016 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.636393e-01 | 0.016 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 9.649721e-01 | 0.015 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 9.662927e-01 | 0.015 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 9.662927e-01 | 0.015 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 9.662927e-01 | 0.015 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.684200e-01 | 0.014 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.702814e-01 | 0.013 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.714263e-01 | 0.013 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.717349e-01 | 0.012 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.720047e-01 | 0.012 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.730313e-01 | 0.012 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.740203e-01 | 0.011 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 9.752138e-01 | 0.011 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 9.758911e-01 | 0.011 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.776273e-01 | 0.010 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.776617e-01 | 0.010 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.784480e-01 | 0.009 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.792387e-01 | 0.009 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 9.807342e-01 | 0.008 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.808609e-01 | 0.008 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 9.812643e-01 | 0.008 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.814411e-01 | 0.008 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.819373e-01 | 0.008 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.827782e-01 | 0.008 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.827782e-01 | 0.008 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.830576e-01 | 0.007 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.832543e-01 | 0.007 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.839468e-01 | 0.007 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 9.851708e-01 | 0.006 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.857151e-01 | 0.006 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 9.862395e-01 | 0.006 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.872137e-01 | 0.006 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.872137e-01 | 0.006 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.874776e-01 | 0.005 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 9.881519e-01 | 0.005 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.882645e-01 | 0.005 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.890031e-01 | 0.005 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.890061e-01 | 0.005 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 9.893552e-01 | 0.005 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.893782e-01 | 0.005 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 9.920672e-01 | 0.003 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.924386e-01 | 0.003 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 9.930436e-01 | 0.003 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.931906e-01 | 0.003 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.932687e-01 | 0.003 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.934904e-01 | 0.003 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.937509e-01 | 0.003 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.937793e-01 | 0.003 | 0 | 0 |
| Translation | R-HSA-72766 | 9.940368e-01 | 0.003 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.943962e-01 | 0.002 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.944011e-01 | 0.002 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.948007e-01 | 0.002 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.958475e-01 | 0.002 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.960572e-01 | 0.002 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 9.961653e-01 | 0.002 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.967540e-01 | 0.001 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.968059e-01 | 0.001 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.969235e-01 | 0.001 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.975164e-01 | 0.001 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 9.975434e-01 | 0.001 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.976776e-01 | 0.001 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.977210e-01 | 0.001 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.980953e-01 | 0.001 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.981108e-01 | 0.001 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.985473e-01 | 0.001 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.989331e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.990991e-01 | 0.000 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.991584e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.992329e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.992329e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.998177e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999103e-01 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.999341e-01 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 9.999385e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.999695e-01 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.999715e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999732e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999810e-01 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.999979e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.110223e-16 | 15.955 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.110223e-16 | 15.955 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.110223e-16 | 15.955 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 3.800738e-12 | 11.420 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 4.611866e-12 | 11.336 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 5.317302e-12 | 11.274 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.077827e-11 | 10.390 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 4.673661e-11 | 10.330 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 5.399636e-11 | 10.268 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 2.052094e-10 | 9.688 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 8.501826e-10 | 9.070 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 8.860738e-10 | 9.053 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.079801e-09 | 8.967 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.505303e-09 | 8.822 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.739325e-09 | 8.760 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.765996e-09 | 8.753 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.006930e-09 | 8.697 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.006930e-09 | 8.697 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 2.045322e-09 | 8.689 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 2.082323e-09 | 8.681 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.629471e-09 | 8.580 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 3.824796e-09 | 8.417 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 4.613625e-09 | 8.336 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 5.280984e-09 | 8.277 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 6.509764e-09 | 8.186 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 6.763814e-09 | 8.170 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 7.391944e-09 | 8.131 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 8.008011e-09 | 8.096 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 8.944277e-09 | 8.048 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.677136e-08 | 7.775 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.677136e-08 | 7.775 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.610800e-08 | 7.793 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.677136e-08 | 7.775 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.291273e-08 | 7.640 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.999474e-08 | 7.523 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 3.218245e-08 | 7.492 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.604525e-08 | 7.443 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 4.417934e-08 | 7.355 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 4.417934e-08 | 7.355 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 4.438443e-08 | 7.353 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 4.460740e-08 | 7.351 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 4.438443e-08 | 7.353 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 4.519908e-08 | 7.345 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 4.641429e-08 | 7.333 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 5.564168e-08 | 7.255 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 5.920900e-08 | 7.228 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.596282e-07 | 6.797 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 2.354558e-07 | 6.628 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.381072e-07 | 6.623 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.506272e-07 | 6.601 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.643489e-07 | 6.578 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 3.110983e-07 | 6.507 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 3.442857e-07 | 6.463 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 3.449642e-07 | 6.462 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 3.386815e-07 | 6.470 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 4.247583e-07 | 6.372 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.651047e-07 | 6.332 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 5.057215e-07 | 6.296 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 5.187054e-07 | 6.285 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 5.485082e-07 | 6.261 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 5.587717e-07 | 6.253 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 5.593326e-07 | 6.252 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 7.251675e-07 | 6.140 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 8.450234e-07 | 6.073 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 8.340900e-07 | 6.079 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 8.705295e-07 | 6.060 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 9.179045e-07 | 6.037 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 9.884114e-07 | 6.005 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 9.957831e-07 | 6.002 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.070511e-06 | 5.970 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.171036e-06 | 5.931 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.388814e-06 | 5.857 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.461835e-06 | 5.835 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.680424e-06 | 5.775 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.777594e-06 | 5.750 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.830724e-06 | 5.737 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 1.838135e-06 | 5.736 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.953183e-06 | 5.709 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 2.132003e-06 | 5.671 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 2.133642e-06 | 5.671 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.275134e-06 | 5.643 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.750930e-06 | 5.561 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.884144e-06 | 5.540 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 3.124269e-06 | 5.505 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 4.367497e-06 | 5.360 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 4.513143e-06 | 5.346 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 4.626061e-06 | 5.335 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 4.732312e-06 | 5.325 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 5.057952e-06 | 5.296 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 5.057952e-06 | 5.296 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 5.214404e-06 | 5.283 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 5.562039e-06 | 5.255 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 6.014786e-06 | 5.221 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 6.108397e-06 | 5.214 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 6.121318e-06 | 5.213 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 6.431367e-06 | 5.192 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.302149e-06 | 5.137 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 6.929725e-06 | 5.159 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 7.457290e-06 | 5.127 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 8.220658e-06 | 5.085 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 8.664653e-06 | 5.062 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 8.960909e-06 | 5.048 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 9.429808e-06 | 5.025 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 9.819179e-06 | 5.008 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.003432e-05 | 4.999 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.032645e-05 | 4.986 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.058638e-05 | 4.975 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.122951e-05 | 4.950 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.247900e-05 | 4.904 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.247900e-05 | 4.904 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 1.189331e-05 | 4.925 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.259099e-05 | 4.900 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.404239e-05 | 4.853 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 1.506266e-05 | 4.822 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.506266e-05 | 4.822 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.776519e-05 | 4.750 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 1.867982e-05 | 4.729 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.935563e-05 | 4.713 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 1.949767e-05 | 4.710 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.956639e-05 | 4.708 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.053061e-05 | 4.688 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 2.381429e-05 | 4.623 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 2.406905e-05 | 4.619 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.550980e-05 | 4.593 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 2.751550e-05 | 4.560 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.601118e-05 | 4.585 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.770250e-05 | 4.557 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.770250e-05 | 4.557 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.787657e-05 | 4.555 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 2.855260e-05 | 4.544 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 2.855260e-05 | 4.544 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 2.857684e-05 | 4.544 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.166387e-05 | 4.499 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 3.058389e-05 | 4.515 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.058266e-05 | 4.515 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.204805e-05 | 4.494 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 3.346407e-05 | 4.475 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 3.348039e-05 | 4.475 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 3.819312e-05 | 4.418 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 3.915214e-05 | 4.407 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 4.439399e-05 | 4.353 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 4.439399e-05 | 4.353 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 4.586667e-05 | 4.339 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.890072e-05 | 4.311 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 5.022145e-05 | 4.299 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 4.984112e-05 | 4.302 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 4.905821e-05 | 4.309 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.230676e-05 | 4.281 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 5.517609e-05 | 4.258 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 6.344189e-05 | 4.198 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 6.678954e-05 | 4.175 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 6.703296e-05 | 4.174 | 0 | 0 |
| Protein folding | R-HSA-391251 | 6.751772e-05 | 4.171 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.820149e-05 | 4.166 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 6.919536e-05 | 4.160 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 7.012327e-05 | 4.154 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 7.012327e-05 | 4.154 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 7.242959e-05 | 4.140 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 7.983419e-05 | 4.098 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 7.981454e-05 | 4.098 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 8.080994e-05 | 4.093 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 8.080994e-05 | 4.093 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 8.392374e-05 | 4.076 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 8.457676e-05 | 4.073 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 8.543319e-05 | 4.068 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 8.622667e-05 | 4.064 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 8.657800e-05 | 4.063 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 8.844446e-05 | 4.053 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 9.091795e-05 | 4.041 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 9.111817e-05 | 4.040 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 9.341987e-05 | 4.030 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 9.537239e-05 | 4.021 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 1.054552e-04 | 3.977 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 9.961362e-05 | 4.002 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.041407e-04 | 3.982 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.041407e-04 | 3.982 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.030208e-04 | 3.987 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.078398e-04 | 3.967 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.078398e-04 | 3.967 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.272130e-04 | 3.895 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 1.338265e-04 | 3.873 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 1.360906e-04 | 3.866 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.434411e-04 | 3.843 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.443495e-04 | 3.841 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.723726e-04 | 3.764 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 1.749326e-04 | 3.757 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.749963e-04 | 3.757 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.878632e-04 | 3.726 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 1.878632e-04 | 3.726 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.901278e-04 | 3.721 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.911191e-04 | 3.719 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.024420e-04 | 3.694 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.123771e-04 | 3.673 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.128073e-04 | 3.672 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 2.232801e-04 | 3.651 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 2.344343e-04 | 3.630 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.365394e-04 | 3.626 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.433577e-04 | 3.614 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 2.459554e-04 | 3.609 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 2.561466e-04 | 3.592 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 2.697711e-04 | 3.569 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.858386e-04 | 3.544 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 2.913353e-04 | 3.536 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.986654e-04 | 3.525 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 3.004136e-04 | 3.522 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.011424e-04 | 3.521 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.122794e-04 | 3.505 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 3.122794e-04 | 3.505 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.133457e-04 | 3.504 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 3.140928e-04 | 3.503 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.293571e-04 | 3.482 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.367791e-04 | 3.473 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 3.481385e-04 | 3.458 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 3.494871e-04 | 3.457 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 3.957690e-04 | 3.403 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 3.653721e-04 | 3.437 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 3.622212e-04 | 3.441 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 3.718614e-04 | 3.430 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 4.085204e-04 | 3.389 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 4.085204e-04 | 3.389 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 4.110804e-04 | 3.386 | 0 | 0 |
| Immune System | R-HSA-168256 | 4.212660e-04 | 3.375 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 4.321632e-04 | 3.364 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.409994e-04 | 3.356 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 4.432660e-04 | 3.353 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 5.248559e-04 | 3.280 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 5.395421e-04 | 3.268 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 5.600415e-04 | 3.252 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 5.979255e-04 | 3.223 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 5.979255e-04 | 3.223 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 6.064915e-04 | 3.217 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 6.182786e-04 | 3.209 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 6.544204e-04 | 3.184 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 6.544204e-04 | 3.184 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 6.582751e-04 | 3.182 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 6.623596e-04 | 3.179 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 6.714070e-04 | 3.173 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 6.912791e-04 | 3.160 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 6.912791e-04 | 3.160 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 6.912791e-04 | 3.160 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 6.862007e-04 | 3.164 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 6.862007e-04 | 3.164 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 6.862007e-04 | 3.164 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 6.862007e-04 | 3.164 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 6.862007e-04 | 3.164 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 6.929542e-04 | 3.159 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 7.498422e-04 | 3.125 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 7.365395e-04 | 3.133 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 7.734075e-04 | 3.112 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 7.859502e-04 | 3.105 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 7.916105e-04 | 3.101 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 8.096793e-04 | 3.092 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 8.602649e-04 | 3.065 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 8.980780e-04 | 3.047 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 9.024298e-04 | 3.045 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 9.958544e-04 | 3.002 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.023296e-03 | 2.990 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.027799e-03 | 2.988 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 1.050000e-03 | 2.979 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.056265e-03 | 2.976 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.056265e-03 | 2.976 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 1.061105e-03 | 2.974 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.161966e-03 | 2.935 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.162002e-03 | 2.935 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 1.162002e-03 | 2.935 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.226139e-03 | 2.911 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.226139e-03 | 2.911 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 1.230958e-03 | 2.910 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.230958e-03 | 2.910 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.313862e-03 | 2.881 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.372775e-03 | 2.862 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.406449e-03 | 2.852 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 1.431602e-03 | 2.844 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 1.444646e-03 | 2.840 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 1.444646e-03 | 2.840 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.457399e-03 | 2.836 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.497940e-03 | 2.825 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.531233e-03 | 2.815 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.558925e-03 | 2.807 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 1.558925e-03 | 2.807 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.651263e-03 | 2.782 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 1.665796e-03 | 2.778 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.721864e-03 | 2.764 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 2.004260e-03 | 2.698 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 2.094676e-03 | 2.679 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.937394e-03 | 2.713 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.959150e-03 | 2.708 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.094676e-03 | 2.679 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 1.829403e-03 | 2.738 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.796783e-03 | 2.746 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 2.094676e-03 | 2.679 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 1.829403e-03 | 2.738 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.884431e-03 | 2.725 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.193232e-03 | 2.659 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 2.196313e-03 | 2.658 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 2.286611e-03 | 2.641 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 2.302798e-03 | 2.638 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 2.316573e-03 | 2.635 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 2.379585e-03 | 2.623 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.450343e-03 | 2.611 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.450343e-03 | 2.611 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 2.483067e-03 | 2.605 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 2.524832e-03 | 2.598 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 2.583654e-03 | 2.588 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 2.615716e-03 | 2.582 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.652368e-03 | 2.576 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 2.724047e-03 | 2.565 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 2.791086e-03 | 2.554 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 2.855200e-03 | 2.544 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 2.993421e-03 | 2.524 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 2.993421e-03 | 2.524 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 3.179038e-03 | 2.498 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 3.211949e-03 | 2.493 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 3.391190e-03 | 2.470 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 3.391190e-03 | 2.470 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.410571e-03 | 2.467 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 3.446786e-03 | 2.463 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 3.500304e-03 | 2.456 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 3.500304e-03 | 2.456 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.518515e-03 | 2.454 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 3.518515e-03 | 2.454 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 3.642370e-03 | 2.439 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.685980e-03 | 2.433 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 3.720422e-03 | 2.429 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 3.762625e-03 | 2.425 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 3.775794e-03 | 2.423 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 3.814621e-03 | 2.419 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 3.917238e-03 | 2.407 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 3.942310e-03 | 2.404 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 4.036033e-03 | 2.394 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 4.065257e-03 | 2.391 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 4.065257e-03 | 2.391 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 4.796822e-03 | 2.319 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 4.704793e-03 | 2.327 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 4.704793e-03 | 2.327 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 4.704793e-03 | 2.327 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 4.704793e-03 | 2.327 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 4.395793e-03 | 2.357 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 4.659435e-03 | 2.332 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 4.438128e-03 | 2.353 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 4.438128e-03 | 2.353 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 4.659435e-03 | 2.332 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 4.987103e-03 | 2.302 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 5.018004e-03 | 2.299 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 5.113259e-03 | 2.291 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 5.113259e-03 | 2.291 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 5.113259e-03 | 2.291 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 5.113259e-03 | 2.291 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 5.142657e-03 | 2.289 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 5.234021e-03 | 2.281 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 5.261398e-03 | 2.279 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 5.660490e-03 | 2.247 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 5.706201e-03 | 2.244 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 5.706201e-03 | 2.244 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 5.904479e-03 | 2.229 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 5.972566e-03 | 2.224 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 6.021197e-03 | 2.220 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 6.047014e-03 | 2.218 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 6.047014e-03 | 2.218 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 6.082598e-03 | 2.216 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 6.140785e-03 | 2.212 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 6.140785e-03 | 2.212 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 6.140785e-03 | 2.212 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 6.207334e-03 | 2.207 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 6.228259e-03 | 2.206 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 6.317612e-03 | 2.199 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 6.360589e-03 | 2.197 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 6.360589e-03 | 2.197 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 6.515221e-03 | 2.186 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 6.572210e-03 | 2.182 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 6.595899e-03 | 2.181 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.689321e-03 | 2.175 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 6.689321e-03 | 2.175 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 6.892681e-03 | 2.162 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 6.937271e-03 | 2.159 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 7.123313e-03 | 2.147 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 7.123313e-03 | 2.147 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 7.123313e-03 | 2.147 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 7.155705e-03 | 2.145 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 7.289118e-03 | 2.137 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 7.292560e-03 | 2.137 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 7.292560e-03 | 2.137 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 7.293992e-03 | 2.137 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 7.330273e-03 | 2.135 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 7.330273e-03 | 2.135 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 7.330273e-03 | 2.135 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 7.426598e-03 | 2.129 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 7.426598e-03 | 2.129 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 7.436232e-03 | 2.129 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 7.608600e-03 | 2.119 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 7.727988e-03 | 2.112 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 7.758111e-03 | 2.110 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 7.758111e-03 | 2.110 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 7.758111e-03 | 2.110 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 7.842491e-03 | 2.106 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 7.844071e-03 | 2.105 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 7.928358e-03 | 2.101 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 8.098265e-03 | 2.092 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 9.194589e-03 | 2.036 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 9.588511e-03 | 2.018 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 9.588511e-03 | 2.018 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.614616e-03 | 2.065 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.015988e-02 | 1.993 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 1.015988e-02 | 1.993 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 1.012436e-02 | 1.995 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 8.294501e-03 | 2.081 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 8.294501e-03 | 2.081 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 8.145980e-03 | 2.089 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 9.588511e-03 | 2.018 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 1.004317e-02 | 1.998 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 8.154123e-03 | 2.089 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 8.199347e-03 | 2.086 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 9.574123e-03 | 2.019 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 8.520628e-03 | 2.070 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 8.154123e-03 | 2.089 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 8.762774e-03 | 2.057 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 8.294501e-03 | 2.081 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.004317e-02 | 1.998 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 9.194589e-03 | 2.036 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 8.985691e-03 | 2.046 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.016366e-02 | 1.993 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.016366e-02 | 1.993 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 1.016366e-02 | 1.993 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 1.016366e-02 | 1.993 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 1.046676e-02 | 1.980 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.101722e-02 | 1.958 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.110236e-02 | 1.955 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.115314e-02 | 1.953 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.128004e-02 | 1.948 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 1.128004e-02 | 1.948 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 1.130398e-02 | 1.947 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.136299e-02 | 1.945 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.159339e-02 | 1.936 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.162947e-02 | 1.934 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 1.175704e-02 | 1.930 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.175704e-02 | 1.930 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.178003e-02 | 1.929 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 1.178003e-02 | 1.929 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.178003e-02 | 1.929 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.185111e-02 | 1.926 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 1.196605e-02 | 1.922 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 1.196605e-02 | 1.922 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 1.198918e-02 | 1.921 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 1.209316e-02 | 1.917 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 1.295514e-02 | 1.888 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.324896e-02 | 1.878 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 1.364851e-02 | 1.865 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.364851e-02 | 1.865 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 1.371905e-02 | 1.863 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.375089e-02 | 1.862 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.375089e-02 | 1.862 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 1.399718e-02 | 1.854 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 1.416899e-02 | 1.849 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 1.562995e-02 | 1.806 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 1.654845e-02 | 1.781 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 1.667782e-02 | 1.778 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.672409e-02 | 1.777 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 1.672409e-02 | 1.777 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 1.675793e-02 | 1.776 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.675793e-02 | 1.776 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.691484e-02 | 1.772 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 1.771101e-02 | 1.752 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.773656e-02 | 1.751 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.789871e-02 | 1.747 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.792417e-02 | 1.747 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.819808e-02 | 1.740 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.840781e-02 | 1.735 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.883714e-02 | 1.725 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.913980e-02 | 1.718 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 1.913980e-02 | 1.718 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.913980e-02 | 1.718 | 0 | 0 |
| Translation | R-HSA-72766 | 1.918737e-02 | 1.717 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.951868e-02 | 1.710 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 1.958653e-02 | 1.708 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 1.962673e-02 | 1.707 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.970899e-02 | 1.705 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.970899e-02 | 1.705 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 1.973724e-02 | 1.705 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 1.980535e-02 | 1.703 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 2.024490e-02 | 1.694 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.024490e-02 | 1.694 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.058941e-02 | 1.686 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 2.097773e-02 | 1.678 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 2.181125e-02 | 1.661 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 2.182818e-02 | 1.661 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.202643e-02 | 1.657 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 2.247818e-02 | 1.648 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 2.657068e-02 | 1.576 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 2.657068e-02 | 1.576 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.657068e-02 | 1.576 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.753633e-02 | 1.560 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 2.596668e-02 | 1.586 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 2.596668e-02 | 1.586 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 2.596668e-02 | 1.586 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 2.349365e-02 | 1.629 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 2.349365e-02 | 1.629 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 2.742334e-02 | 1.562 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 3.007457e-02 | 1.522 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 3.007457e-02 | 1.522 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 3.007457e-02 | 1.522 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 3.007457e-02 | 1.522 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.554183e-02 | 1.593 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.680225e-02 | 1.572 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.263809e-02 | 1.645 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.793551e-02 | 1.554 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 2.338653e-02 | 1.631 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.888986e-02 | 1.539 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.789160e-02 | 1.555 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 2.271779e-02 | 1.644 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 2.261585e-02 | 1.646 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 2.789160e-02 | 1.555 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 2.596668e-02 | 1.586 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 3.007457e-02 | 1.522 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 2.310605e-02 | 1.636 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 2.310605e-02 | 1.636 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 2.560593e-02 | 1.592 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 2.742334e-02 | 1.562 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 2.847594e-02 | 1.546 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.680225e-02 | 1.572 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 2.263809e-02 | 1.645 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 2.348555e-02 | 1.629 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 2.321360e-02 | 1.634 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 2.793551e-02 | 1.554 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 2.742334e-02 | 1.562 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 3.000338e-02 | 1.523 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 2.742334e-02 | 1.562 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 2.633487e-02 | 1.579 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 3.029431e-02 | 1.519 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 3.074503e-02 | 1.512 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 3.086235e-02 | 1.511 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 3.164911e-02 | 1.500 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 3.164911e-02 | 1.500 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 3.164911e-02 | 1.500 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 3.164911e-02 | 1.500 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.176491e-02 | 1.498 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 3.235849e-02 | 1.490 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.273947e-02 | 1.485 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 3.318129e-02 | 1.479 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 3.318129e-02 | 1.479 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.322636e-02 | 1.479 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 3.322636e-02 | 1.479 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.322636e-02 | 1.479 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 3.357063e-02 | 1.474 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 3.357063e-02 | 1.474 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 3.359217e-02 | 1.474 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 3.377381e-02 | 1.471 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.392981e-02 | 1.469 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 3.472203e-02 | 1.459 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 3.482733e-02 | 1.458 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 3.537367e-02 | 1.451 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 3.537367e-02 | 1.451 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 3.579936e-02 | 1.446 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 3.610384e-02 | 1.442 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 3.610384e-02 | 1.442 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 3.610384e-02 | 1.442 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 3.610384e-02 | 1.442 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 3.671115e-02 | 1.435 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 3.688221e-02 | 1.433 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 3.688221e-02 | 1.433 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 3.768486e-02 | 1.424 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 3.783345e-02 | 1.422 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 3.783345e-02 | 1.422 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 3.783345e-02 | 1.422 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 3.803291e-02 | 1.420 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.864460e-02 | 1.413 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 3.912725e-02 | 1.408 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.925792e-02 | 1.406 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 3.929565e-02 | 1.406 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 3.929565e-02 | 1.406 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 3.929565e-02 | 1.406 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 3.929565e-02 | 1.406 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 3.929565e-02 | 1.406 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 3.929565e-02 | 1.406 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 3.929565e-02 | 1.406 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 3.929565e-02 | 1.406 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 3.929565e-02 | 1.406 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 3.929565e-02 | 1.406 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 3.929565e-02 | 1.406 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 3.929565e-02 | 1.406 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 3.929565e-02 | 1.406 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 3.960804e-02 | 1.402 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 4.026952e-02 | 1.395 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 4.150990e-02 | 1.382 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 4.150990e-02 | 1.382 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.243534e-02 | 1.372 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 4.273154e-02 | 1.369 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 4.273154e-02 | 1.369 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 4.330635e-02 | 1.363 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 4.460547e-02 | 1.351 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 4.474955e-02 | 1.349 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 4.474955e-02 | 1.349 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 4.474955e-02 | 1.349 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 4.651170e-02 | 1.332 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.683234e-02 | 1.329 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 4.683234e-02 | 1.329 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 4.683234e-02 | 1.329 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 4.725607e-02 | 1.326 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 4.729218e-02 | 1.325 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 4.729218e-02 | 1.325 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 4.729218e-02 | 1.325 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 4.748492e-02 | 1.323 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 4.847896e-02 | 1.314 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 4.847896e-02 | 1.314 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 4.856105e-02 | 1.314 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 4.942880e-02 | 1.306 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 5.030596e-02 | 1.298 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 5.380924e-02 | 1.269 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 5.380924e-02 | 1.269 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 5.380924e-02 | 1.269 | 0 | 0 |
| UNC93B1 deficiency - HSE | R-HSA-5602415 | 5.380924e-02 | 1.269 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 5.380924e-02 | 1.269 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 5.380924e-02 | 1.269 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 5.380924e-02 | 1.269 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 6.721554e-02 | 1.173 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 6.721554e-02 | 1.173 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 6.721554e-02 | 1.173 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 6.721554e-02 | 1.173 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 6.721554e-02 | 1.173 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 6.721554e-02 | 1.173 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 6.335220e-02 | 1.198 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 5.605530e-02 | 1.251 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 5.605530e-02 | 1.251 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 5.605530e-02 | 1.251 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 5.605530e-02 | 1.251 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 5.605530e-02 | 1.251 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 5.605530e-02 | 1.251 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 7.492754e-02 | 1.125 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 7.492754e-02 | 1.125 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 7.492754e-02 | 1.125 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 7.492754e-02 | 1.125 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 7.492754e-02 | 1.125 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 6.317729e-02 | 1.199 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 6.317729e-02 | 1.199 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 6.669962e-02 | 1.176 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 6.669962e-02 | 1.176 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 6.669962e-02 | 1.176 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 6.669962e-02 | 1.176 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 6.669962e-02 | 1.176 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 6.669962e-02 | 1.176 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 5.562397e-02 | 1.255 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 5.562397e-02 | 1.255 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 5.661402e-02 | 1.247 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 5.663387e-02 | 1.247 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 5.600158e-02 | 1.252 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 6.715448e-02 | 1.173 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 5.492926e-02 | 1.260 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 6.571522e-02 | 1.182 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 7.645820e-02 | 1.117 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 7.231461e-02 | 1.141 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 7.231461e-02 | 1.141 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 7.231461e-02 | 1.141 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 5.262184e-02 | 1.279 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 6.391813e-02 | 1.194 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 6.823478e-02 | 1.166 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 5.479126e-02 | 1.261 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 7.105623e-02 | 1.148 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 5.356184e-02 | 1.271 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 6.804689e-02 | 1.167 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 7.283406e-02 | 1.138 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 5.723157e-02 | 1.242 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 6.669962e-02 | 1.176 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 6.391813e-02 | 1.194 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 7.472815e-02 | 1.127 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 6.391813e-02 | 1.194 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 5.564269e-02 | 1.255 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 7.333747e-02 | 1.135 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 5.974583e-02 | 1.224 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 6.823478e-02 | 1.166 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 6.669962e-02 | 1.176 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 6.189773e-02 | 1.208 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 6.189773e-02 | 1.208 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 7.492754e-02 | 1.125 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 5.299065e-02 | 1.276 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 5.299065e-02 | 1.276 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 7.029760e-02 | 1.153 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 5.752607e-02 | 1.240 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 6.071043e-02 | 1.217 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 7.173319e-02 | 1.144 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 5.505632e-02 | 1.259 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 6.262197e-02 | 1.203 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 5.774117e-02 | 1.239 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 6.391813e-02 | 1.194 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 7.748504e-02 | 1.111 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 6.372515e-02 | 1.196 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 5.852483e-02 | 1.233 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 6.391813e-02 | 1.194 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 6.541153e-02 | 1.184 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 5.446510e-02 | 1.264 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 5.605530e-02 | 1.251 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 7.492754e-02 | 1.125 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 5.752607e-02 | 1.240 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 5.770062e-02 | 1.239 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 5.822447e-02 | 1.235 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 5.200035e-02 | 1.284 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.217228e-02 | 1.283 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 5.317282e-02 | 1.274 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 7.399056e-02 | 1.131 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 7.399056e-02 | 1.131 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 5.185736e-02 | 1.285 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 6.204735e-02 | 1.207 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 5.770062e-02 | 1.239 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 6.814745e-02 | 1.167 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 6.335220e-02 | 1.198 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 6.335220e-02 | 1.198 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 6.335220e-02 | 1.198 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 7.645820e-02 | 1.117 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 7.927317e-02 | 1.101 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 8.022463e-02 | 1.096 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 8.079953e-02 | 1.093 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 8.079953e-02 | 1.093 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 8.079953e-02 | 1.093 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 8.105483e-02 | 1.091 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 8.204388e-02 | 1.086 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 8.211549e-02 | 1.086 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 8.211549e-02 | 1.086 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 8.211549e-02 | 1.086 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 8.264640e-02 | 1.083 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 8.327679e-02 | 1.079 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 8.327679e-02 | 1.079 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 8.466162e-02 | 1.072 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 8.490964e-02 | 1.071 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 8.501302e-02 | 1.071 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 8.750923e-02 | 1.058 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 8.750923e-02 | 1.058 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 8.824560e-02 | 1.054 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 8.824560e-02 | 1.054 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 8.824560e-02 | 1.054 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 8.829128e-02 | 1.054 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 8.850008e-02 | 1.053 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 8.850008e-02 | 1.053 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.171321e-02 | 1.038 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 9.190454e-02 | 1.037 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 9.190454e-02 | 1.037 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.327937e-02 | 1.030 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 9.491646e-02 | 1.023 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 9.681677e-02 | 1.014 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 9.681677e-02 | 1.014 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 9.681677e-02 | 1.014 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 9.681677e-02 | 1.014 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 9.681677e-02 | 1.014 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 9.681677e-02 | 1.014 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 9.761568e-02 | 1.010 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 9.761568e-02 | 1.010 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 9.761568e-02 | 1.010 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 9.831452e-02 | 1.007 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 9.940913e-02 | 1.003 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.940913e-02 | 1.003 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 9.940913e-02 | 1.003 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 9.958897e-02 | 1.002 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 9.958897e-02 | 1.002 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 9.958897e-02 | 1.002 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 9.958897e-02 | 1.002 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 9.958897e-02 | 1.002 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 9.958897e-02 | 1.002 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 9.958897e-02 | 1.002 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 1.018707e-01 | 0.992 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.018707e-01 | 0.992 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 1.018707e-01 | 0.992 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 1.018707e-01 | 0.992 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 1.018707e-01 | 0.992 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.020821e-01 | 0.991 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.030874e-01 | 0.987 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 1.075387e-01 | 0.968 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 1.075387e-01 | 0.968 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 1.075387e-01 | 0.968 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 1.075387e-01 | 0.968 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 1.099024e-01 | 0.959 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.110204e-01 | 0.955 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 1.147385e-01 | 0.940 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 1.149620e-01 | 0.939 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 1.149620e-01 | 0.939 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 1.172217e-01 | 0.931 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 1.172217e-01 | 0.931 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.172217e-01 | 0.931 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 1.172217e-01 | 0.931 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 1.172217e-01 | 0.931 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.185341e-01 | 0.926 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 1.209774e-01 | 0.917 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.209774e-01 | 0.917 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.211847e-01 | 0.917 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 1.211847e-01 | 0.917 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.211847e-01 | 0.917 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 1.211847e-01 | 0.917 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 1.211847e-01 | 0.917 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 1.211847e-01 | 0.917 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 1.211847e-01 | 0.917 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 1.222688e-01 | 0.913 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.227768e-01 | 0.911 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 1.266972e-01 | 0.897 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.295690e-01 | 0.887 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.691041e-01 | 0.772 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.691041e-01 | 0.772 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.691041e-01 | 0.772 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.691041e-01 | 0.772 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.691041e-01 | 0.772 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.691041e-01 | 0.772 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.691041e-01 | 0.772 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 1.691041e-01 | 0.772 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.691041e-01 | 0.772 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.691041e-01 | 0.772 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.691041e-01 | 0.772 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.691041e-01 | 0.772 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.691041e-01 | 0.772 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.691041e-01 | 0.772 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.691041e-01 | 0.772 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.691041e-01 | 0.772 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.691041e-01 | 0.772 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.691041e-01 | 0.772 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.691041e-01 | 0.772 | 0 | 0 |
| TLR3 deficiency - HSE | R-HSA-5602410 | 1.691041e-01 | 0.772 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.691041e-01 | 0.772 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.691041e-01 | 0.772 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.691041e-01 | 0.772 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.691041e-01 | 0.772 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.691041e-01 | 0.772 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.691041e-01 | 0.772 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.691041e-01 | 0.772 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.691041e-01 | 0.772 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.691041e-01 | 0.772 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.691041e-01 | 0.772 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.691041e-01 | 0.772 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.691041e-01 | 0.772 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.691041e-01 | 0.772 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.691041e-01 | 0.772 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.691041e-01 | 0.772 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.691041e-01 | 0.772 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 1.691041e-01 | 0.772 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.691041e-01 | 0.772 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.701565e-01 | 0.769 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 1.701565e-01 | 0.769 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 1.701565e-01 | 0.769 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 1.701565e-01 | 0.769 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 1.701565e-01 | 0.769 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 1.701565e-01 | 0.769 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 1.701565e-01 | 0.769 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 1.701565e-01 | 0.769 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 1.420965e-01 | 0.847 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 1.420965e-01 | 0.847 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 1.420965e-01 | 0.847 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 1.420965e-01 | 0.847 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.420965e-01 | 0.847 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 1.420965e-01 | 0.847 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 1.420965e-01 | 0.847 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 2.371221e-01 | 0.625 | 0 | 0 |
| Signaling by FGFR1 amplification mutants | R-HSA-1839120 | 2.371221e-01 | 0.625 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 2.371221e-01 | 0.625 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 2.371221e-01 | 0.625 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 2.371221e-01 | 0.625 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 2.371221e-01 | 0.625 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 2.371221e-01 | 0.625 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 1.866064e-01 | 0.729 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 1.866064e-01 | 0.729 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 1.866064e-01 | 0.729 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 1.866064e-01 | 0.729 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.496813e-01 | 0.825 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 1.496813e-01 | 0.825 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 1.851196e-01 | 0.733 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 2.341213e-01 | 0.631 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 2.341213e-01 | 0.631 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 2.341213e-01 | 0.631 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.448786e-01 | 0.839 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.448786e-01 | 0.839 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.786255e-01 | 0.748 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 2.229395e-01 | 0.652 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 2.229395e-01 | 0.652 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.394114e-01 | 0.856 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 1.333651e-01 | 0.875 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 2.103139e-01 | 0.677 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 1.619328e-01 | 0.791 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 1.534263e-01 | 0.814 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 1.978343e-01 | 0.704 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 1.978343e-01 | 0.704 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 1.978343e-01 | 0.704 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 1.978343e-01 | 0.704 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 1.978343e-01 | 0.704 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 1.373297e-01 | 0.862 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 2.436350e-01 | 0.613 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 2.266601e-01 | 0.645 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 2.266601e-01 | 0.645 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 2.113542e-01 | 0.675 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 2.113542e-01 | 0.675 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 2.113542e-01 | 0.675 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 1.457766e-01 | 0.836 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.974805e-01 | 0.704 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 1.437975e-01 | 0.842 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 2.379301e-01 | 0.624 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 2.062837e-01 | 0.686 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 2.062837e-01 | 0.686 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 1.448898e-01 | 0.839 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 2.460015e-01 | 0.609 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 1.350760e-01 | 0.869 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 2.343618e-01 | 0.630 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 1.719782e-01 | 0.765 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 2.596165e-01 | 0.586 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 2.074860e-01 | 0.683 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 2.012945e-01 | 0.696 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 1.920598e-01 | 0.717 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 1.402858e-01 | 0.853 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 2.113542e-01 | 0.675 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 1.534263e-01 | 0.814 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 1.487167e-01 | 0.828 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 1.394114e-01 | 0.856 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 1.927532e-01 | 0.715 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 1.748334e-01 | 0.757 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 2.379301e-01 | 0.624 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 1.431362e-01 | 0.844 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.619328e-01 | 0.791 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 1.786255e-01 | 0.748 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.212472e-01 | 0.655 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 2.062837e-01 | 0.686 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.448898e-01 | 0.839 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.487567e-01 | 0.828 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 1.489302e-01 | 0.827 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 2.229395e-01 | 0.652 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.927532e-01 | 0.715 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 2.170234e-01 | 0.663 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.911851e-01 | 0.719 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.647808e-01 | 0.783 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.496813e-01 | 0.825 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 2.229395e-01 | 0.652 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 1.492914e-01 | 0.826 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 1.420965e-01 | 0.847 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.457766e-01 | 0.836 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 2.620720e-01 | 0.582 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 1.616827e-01 | 0.791 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 2.113542e-01 | 0.675 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 1.489093e-01 | 0.827 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.461698e-01 | 0.835 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 1.669117e-01 | 0.778 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 2.341213e-01 | 0.631 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 2.341213e-01 | 0.631 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 1.786255e-01 | 0.748 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 1.786255e-01 | 0.748 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 1.786255e-01 | 0.748 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 1.786255e-01 | 0.748 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 2.229395e-01 | 0.652 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.927532e-01 | 0.715 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 2.229395e-01 | 0.652 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 2.062837e-01 | 0.686 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 2.263305e-01 | 0.645 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.460015e-01 | 0.609 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 1.669117e-01 | 0.778 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 2.500768e-01 | 0.602 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 1.669117e-01 | 0.778 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 1.669117e-01 | 0.778 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 2.291055e-01 | 0.640 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 2.374297e-01 | 0.624 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 1.797193e-01 | 0.745 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 1.563021e-01 | 0.806 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 2.371221e-01 | 0.625 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 2.371221e-01 | 0.625 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 2.113542e-01 | 0.675 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.823971e-01 | 0.739 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 2.279698e-01 | 0.642 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 2.133393e-01 | 0.671 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 2.371272e-01 | 0.625 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 2.170234e-01 | 0.663 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 2.331037e-01 | 0.632 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 1.859651e-01 | 0.731 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 2.331037e-01 | 0.632 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 2.596165e-01 | 0.586 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.451940e-01 | 0.838 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.487167e-01 | 0.828 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 1.866064e-01 | 0.729 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 2.204844e-01 | 0.657 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 1.927532e-01 | 0.715 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 2.371272e-01 | 0.625 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.619328e-01 | 0.791 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 2.460015e-01 | 0.609 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.911851e-01 | 0.719 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.986193e-01 | 0.702 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 2.541458e-01 | 0.595 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.387725e-01 | 0.622 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 1.701565e-01 | 0.769 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 1.420965e-01 | 0.847 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 2.371221e-01 | 0.625 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 1.866064e-01 | 0.729 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 1.851196e-01 | 0.733 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 1.786255e-01 | 0.748 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 1.786255e-01 | 0.748 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 2.266601e-01 | 0.645 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.457766e-01 | 0.836 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 1.639109e-01 | 0.785 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.487567e-01 | 0.828 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 2.185581e-01 | 0.660 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.731855e-01 | 0.761 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 2.170234e-01 | 0.663 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 1.420289e-01 | 0.848 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 1.619328e-01 | 0.791 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 1.748334e-01 | 0.757 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.379301e-01 | 0.624 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.779493e-01 | 0.750 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 2.371221e-01 | 0.625 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 2.291055e-01 | 0.640 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 2.436350e-01 | 0.613 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 2.485510e-01 | 0.605 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 2.250318e-01 | 0.648 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 2.593470e-01 | 0.586 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 1.804401e-01 | 0.744 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 1.732749e-01 | 0.761 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 2.185581e-01 | 0.660 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 2.084313e-01 | 0.681 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.616827e-01 | 0.791 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 2.387557e-01 | 0.622 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 1.478235e-01 | 0.830 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 1.420965e-01 | 0.847 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 2.379301e-01 | 0.624 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 1.870190e-01 | 0.728 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 1.496813e-01 | 0.825 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 1.448786e-01 | 0.839 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 2.625311e-01 | 0.581 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 2.625311e-01 | 0.581 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 2.650366e-01 | 0.577 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.666578e-01 | 0.574 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 2.748809e-01 | 0.561 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 2.782175e-01 | 0.556 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 2.782175e-01 | 0.556 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 2.782175e-01 | 0.556 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 2.789376e-01 | 0.554 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 2.789376e-01 | 0.554 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 2.816789e-01 | 0.550 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 2.834489e-01 | 0.548 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 2.834489e-01 | 0.548 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 2.834489e-01 | 0.548 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 2.834489e-01 | 0.548 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 2.834489e-01 | 0.548 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 2.834489e-01 | 0.548 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 2.834489e-01 | 0.548 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 2.834489e-01 | 0.548 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.840545e-01 | 0.547 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.877830e-01 | 0.541 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 2.877830e-01 | 0.541 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 2.877830e-01 | 0.541 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 2.877830e-01 | 0.541 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.877830e-01 | 0.541 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 2.877830e-01 | 0.541 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 2.939089e-01 | 0.532 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 2.939089e-01 | 0.532 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.979054e-01 | 0.526 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.979054e-01 | 0.526 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 2.979054e-01 | 0.526 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 2.988300e-01 | 0.525 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 3.030866e-01 | 0.518 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.030866e-01 | 0.518 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 3.032989e-01 | 0.518 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 3.034005e-01 | 0.518 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 3.051759e-01 | 0.515 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 3.051759e-01 | 0.515 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 3.051759e-01 | 0.515 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 3.051759e-01 | 0.515 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 3.051759e-01 | 0.515 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 3.051759e-01 | 0.515 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 3.096199e-01 | 0.509 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 3.096199e-01 | 0.509 | 0 | 0 |
| MGMT-mediated DNA damage reversal | R-HSA-5657655 | 3.096199e-01 | 0.509 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 3.096199e-01 | 0.509 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 3.096199e-01 | 0.509 | 0 | 0 |
| Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) | R-HSA-5619110 | 3.096199e-01 | 0.509 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 3.096199e-01 | 0.509 | 0 | 0 |
| SARS-CoV-1 targets PDZ proteins in cell-cell junction | R-HSA-9692912 | 3.096199e-01 | 0.509 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 3.096199e-01 | 0.509 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 3.096199e-01 | 0.509 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 3.096199e-01 | 0.509 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 3.096199e-01 | 0.509 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 3.096199e-01 | 0.509 | 0 | 0 |
| TGFBR2 MSI Frameshift Mutants in Cancer | R-HSA-3642279 | 3.096199e-01 | 0.509 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 3.096199e-01 | 0.509 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 3.096199e-01 | 0.509 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 3.136913e-01 | 0.503 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 3.136913e-01 | 0.503 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 3.195677e-01 | 0.495 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 3.195677e-01 | 0.495 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 3.195677e-01 | 0.495 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 3.195677e-01 | 0.495 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 3.195677e-01 | 0.495 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 3.195677e-01 | 0.495 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 3.225862e-01 | 0.491 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 3.237349e-01 | 0.490 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.247596e-01 | 0.488 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 3.335287e-01 | 0.477 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 3.335287e-01 | 0.477 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 3.335287e-01 | 0.477 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 3.335287e-01 | 0.477 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 3.335287e-01 | 0.477 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 3.335287e-01 | 0.477 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 3.335287e-01 | 0.477 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 3.361005e-01 | 0.474 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 3.427013e-01 | 0.465 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 3.427013e-01 | 0.465 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 3.443797e-01 | 0.463 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 3.446812e-01 | 0.463 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 3.446812e-01 | 0.463 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 3.446812e-01 | 0.463 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 3.446812e-01 | 0.463 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 3.446812e-01 | 0.463 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 3.446812e-01 | 0.463 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 3.446812e-01 | 0.463 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 3.446812e-01 | 0.463 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 3.464802e-01 | 0.460 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 3.496979e-01 | 0.456 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 3.496979e-01 | 0.456 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 3.496979e-01 | 0.456 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 3.497011e-01 | 0.456 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.497011e-01 | 0.456 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 3.497011e-01 | 0.456 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 3.510524e-01 | 0.455 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 3.513302e-01 | 0.454 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 3.518291e-01 | 0.454 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 3.520162e-01 | 0.453 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 3.523899e-01 | 0.453 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 3.595789e-01 | 0.444 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 3.681484e-01 | 0.434 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 3.720354e-01 | 0.429 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 3.720354e-01 | 0.429 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 3.720354e-01 | 0.429 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 3.720354e-01 | 0.429 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 3.720354e-01 | 0.429 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 3.720354e-01 | 0.429 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 3.720354e-01 | 0.429 | 0 | 0 |
| Toxicity of botulinum toxin type G (botG) | R-HSA-5250989 | 3.720354e-01 | 0.429 | 0 | 0 |
| Pyrophosphate hydrolysis | R-HSA-71737 | 3.720354e-01 | 0.429 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 3.720354e-01 | 0.429 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 3.739296e-01 | 0.427 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 3.739296e-01 | 0.427 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 3.739296e-01 | 0.427 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 3.739296e-01 | 0.427 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 3.755367e-01 | 0.425 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 3.767752e-01 | 0.424 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 3.828340e-01 | 0.417 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 3.834530e-01 | 0.416 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 3.834530e-01 | 0.416 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 3.834530e-01 | 0.416 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 3.834530e-01 | 0.416 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 3.834530e-01 | 0.416 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.834530e-01 | 0.416 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 3.834530e-01 | 0.416 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 3.834530e-01 | 0.416 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.834530e-01 | 0.416 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.834530e-01 | 0.416 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 3.845904e-01 | 0.415 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 3.851852e-01 | 0.414 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 3.851852e-01 | 0.414 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 3.858983e-01 | 0.414 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 3.858983e-01 | 0.414 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 3.858983e-01 | 0.414 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 3.858983e-01 | 0.414 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 3.858983e-01 | 0.414 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 3.861646e-01 | 0.413 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 3.861646e-01 | 0.413 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 3.861646e-01 | 0.413 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 3.882727e-01 | 0.411 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 3.901729e-01 | 0.409 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 3.920774e-01 | 0.407 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 3.984300e-01 | 0.400 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 4.026353e-01 | 0.395 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 4.071500e-01 | 0.390 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 4.118734e-01 | 0.385 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 4.118734e-01 | 0.385 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 4.118734e-01 | 0.385 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 4.158199e-01 | 0.381 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 4.168181e-01 | 0.380 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.173648e-01 | 0.379 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 4.219792e-01 | 0.375 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 4.219792e-01 | 0.375 | 0 | 0 |
| PKA activation | R-HSA-163615 | 4.219792e-01 | 0.375 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 4.219792e-01 | 0.375 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 4.219792e-01 | 0.375 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 4.219792e-01 | 0.375 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 4.219792e-01 | 0.375 | 0 | 0 |
| FGFR4 mutant receptor activation | R-HSA-1839128 | 4.263792e-01 | 0.370 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 4.263792e-01 | 0.370 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 4.263792e-01 | 0.370 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 4.263792e-01 | 0.370 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 4.263792e-01 | 0.370 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 4.263792e-01 | 0.370 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective HK1 causes hexokinase deficiency (HK deficiency) | R-HSA-5619056 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 4.263792e-01 | 0.370 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 4.263792e-01 | 0.370 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 4.263792e-01 | 0.370 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 4.263792e-01 | 0.370 | 0 | 0 |
| Beta-ketothiolase deficiency | R-HSA-9915355 | 4.263792e-01 | 0.370 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 4.263792e-01 | 0.370 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 4.263792e-01 | 0.370 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5619101 | 4.263792e-01 | 0.370 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 4.263792e-01 | 0.370 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 4.263792e-01 | 0.370 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 4.263792e-01 | 0.370 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 4.263792e-01 | 0.370 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 4.263792e-01 | 0.370 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 4.263792e-01 | 0.370 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5660686 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective SLC12A3 causes Gitelman syndrome (GS) | R-HSA-5619087 | 4.263792e-01 | 0.370 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 4.263792e-01 | 0.370 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 4.263792e-01 | 0.370 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 4.263792e-01 | 0.370 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 4.263792e-01 | 0.370 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 4.272922e-01 | 0.369 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 4.324712e-01 | 0.364 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 4.324712e-01 | 0.364 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 4.324712e-01 | 0.364 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 4.324712e-01 | 0.364 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 4.324712e-01 | 0.364 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 4.344485e-01 | 0.362 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 4.361589e-01 | 0.360 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 4.361589e-01 | 0.360 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 4.361589e-01 | 0.360 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 4.361589e-01 | 0.360 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 4.361589e-01 | 0.360 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 4.361589e-01 | 0.360 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 4.361589e-01 | 0.360 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 4.361589e-01 | 0.360 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 4.361589e-01 | 0.360 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 4.361589e-01 | 0.360 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 4.361589e-01 | 0.360 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 4.361589e-01 | 0.360 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 4.361589e-01 | 0.360 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 4.361589e-01 | 0.360 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 4.391417e-01 | 0.357 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.415507e-01 | 0.355 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 4.415507e-01 | 0.355 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.415507e-01 | 0.355 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 4.415507e-01 | 0.355 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 4.415507e-01 | 0.355 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 4.415507e-01 | 0.355 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 4.437415e-01 | 0.353 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 4.471547e-01 | 0.350 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 4.491002e-01 | 0.348 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 4.514241e-01 | 0.345 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 4.570239e-01 | 0.340 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 4.570239e-01 | 0.340 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 4.570239e-01 | 0.340 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 4.621860e-01 | 0.335 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 4.636905e-01 | 0.334 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 4.641046e-01 | 0.333 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 4.676685e-01 | 0.330 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 4.676685e-01 | 0.330 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 4.709710e-01 | 0.327 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 4.710761e-01 | 0.327 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 4.799846e-01 | 0.319 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.799846e-01 | 0.319 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 4.799846e-01 | 0.319 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 4.809732e-01 | 0.318 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 4.809732e-01 | 0.318 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 4.892862e-01 | 0.310 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 4.893477e-01 | 0.310 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 4.920879e-01 | 0.308 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 4.920879e-01 | 0.308 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 4.920879e-01 | 0.308 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 4.920879e-01 | 0.308 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 4.920879e-01 | 0.308 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 4.926823e-01 | 0.307 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 4.965598e-01 | 0.304 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 4.965598e-01 | 0.304 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 4.965598e-01 | 0.304 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 4.965598e-01 | 0.304 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 4.965598e-01 | 0.304 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 4.965598e-01 | 0.304 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 4.965598e-01 | 0.304 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 4.965598e-01 | 0.304 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 4.965598e-01 | 0.304 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 4.965598e-01 | 0.304 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 4.965598e-01 | 0.304 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 4.965598e-01 | 0.304 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 4.965598e-01 | 0.304 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 4.965598e-01 | 0.304 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 4.965598e-01 | 0.304 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.999893e-01 | 0.301 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 4.999893e-01 | 0.301 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 4.999893e-01 | 0.301 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 5.052386e-01 | 0.297 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 5.052386e-01 | 0.297 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 5.069603e-01 | 0.295 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 5.069603e-01 | 0.295 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 5.069603e-01 | 0.295 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 5.069603e-01 | 0.295 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 5.069603e-01 | 0.295 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 5.122616e-01 | 0.291 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 5.122616e-01 | 0.291 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 5.161192e-01 | 0.287 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 5.161192e-01 | 0.287 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 5.192729e-01 | 0.285 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 5.211817e-01 | 0.283 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 5.233973e-01 | 0.281 | 0 | 0 |
| NTF3 activates NTRK2 (TRKB) signaling | R-HSA-9025046 | 5.233973e-01 | 0.281 | 0 | 0 |
| NTF4 activates NTRK2 (TRKB) signaling | R-HSA-9026357 | 5.233973e-01 | 0.281 | 0 | 0 |
| BDNF activates NTRK2 (TRKB) signaling | R-HSA-9024909 | 5.233973e-01 | 0.281 | 0 | 0 |
| NTF3 activates NTRK3 signaling | R-HSA-9034013 | 5.233973e-01 | 0.281 | 0 | 0 |
| Defective ALG9 causes CDG-1l | R-HSA-4720454 | 5.233973e-01 | 0.281 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 5.233973e-01 | 0.281 | 0 | 0 |
| Defective SLC12A1 causes Bartter syndrome 1 (BS1) | R-HSA-5619104 | 5.233973e-01 | 0.281 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 5.233973e-01 | 0.281 | 0 | 0 |
| Glycogen storage disease type IV (GBE1) | R-HSA-3878781 | 5.233973e-01 | 0.281 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 5.233973e-01 | 0.281 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 5.233973e-01 | 0.281 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 5.233973e-01 | 0.281 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 5.233973e-01 | 0.281 | 0 | 0 |
| Defective ABCC8 can cause hypo- and hyper-glycemias | R-HSA-5683177 | 5.233973e-01 | 0.281 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 5.233973e-01 | 0.281 | 0 | 0 |
| Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization | R-HSA-180897 | 5.233973e-01 | 0.281 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 5.255345e-01 | 0.279 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 5.255345e-01 | 0.279 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 5.255345e-01 | 0.279 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 5.255345e-01 | 0.279 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 5.255345e-01 | 0.279 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 5.255345e-01 | 0.279 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 5.255345e-01 | 0.279 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 5.266499e-01 | 0.278 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 5.268366e-01 | 0.278 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 5.268366e-01 | 0.278 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 5.268366e-01 | 0.278 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 5.301802e-01 | 0.276 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 5.423990e-01 | 0.266 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 5.424645e-01 | 0.266 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 5.426850e-01 | 0.265 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.441302e-01 | 0.264 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 5.491101e-01 | 0.260 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 5.526632e-01 | 0.258 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 5.526632e-01 | 0.258 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 5.526632e-01 | 0.258 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 5.526632e-01 | 0.258 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 5.526632e-01 | 0.258 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 5.526632e-01 | 0.258 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 5.526632e-01 | 0.258 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 5.526632e-01 | 0.258 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 5.526632e-01 | 0.258 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 5.526632e-01 | 0.258 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 5.526632e-01 | 0.258 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 5.592149e-01 | 0.252 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 5.592149e-01 | 0.252 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 5.599374e-01 | 0.252 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 5.599374e-01 | 0.252 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 5.642926e-01 | 0.248 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 5.687867e-01 | 0.245 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 5.687867e-01 | 0.245 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 5.687867e-01 | 0.245 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 5.687867e-01 | 0.245 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 5.687867e-01 | 0.245 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 5.687867e-01 | 0.245 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 5.687867e-01 | 0.245 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 5.687867e-01 | 0.245 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 5.687867e-01 | 0.245 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 5.687867e-01 | 0.245 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 5.687867e-01 | 0.245 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 5.687867e-01 | 0.245 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 5.687867e-01 | 0.245 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 5.793332e-01 | 0.237 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 5.812589e-01 | 0.236 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 5.812589e-01 | 0.236 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 5.833978e-01 | 0.234 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 5.833978e-01 | 0.234 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 5.918344e-01 | 0.228 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 5.918344e-01 | 0.228 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 5.918344e-01 | 0.228 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 5.918344e-01 | 0.228 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 5.931295e-01 | 0.227 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 6.011830e-01 | 0.221 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 6.011830e-01 | 0.221 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 6.040110e-01 | 0.219 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 6.040110e-01 | 0.219 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 6.040110e-01 | 0.219 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 6.040110e-01 | 0.219 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 6.040110e-01 | 0.219 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 6.040110e-01 | 0.219 | 0 | 0 |
| Activation of BMF and translocation to mitochondria | R-HSA-139910 | 6.040110e-01 | 0.219 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 6.040110e-01 | 0.219 | 0 | 0 |
| Intracellular oxygen transport | R-HSA-8981607 | 6.040110e-01 | 0.219 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 6.040110e-01 | 0.219 | 0 | 0 |
| RSK activation | R-HSA-444257 | 6.041951e-01 | 0.219 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 6.041951e-01 | 0.219 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 6.041951e-01 | 0.219 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 6.041951e-01 | 0.219 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 6.041951e-01 | 0.219 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 6.041951e-01 | 0.219 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 6.041951e-01 | 0.219 | 0 | 0 |
| Toxicity of botulinum toxin type B (botB) | R-HSA-5250958 | 6.041951e-01 | 0.219 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 6.041951e-01 | 0.219 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 6.041951e-01 | 0.219 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 6.041951e-01 | 0.219 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 6.041951e-01 | 0.219 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 6.041951e-01 | 0.219 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 6.041951e-01 | 0.219 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 6.041951e-01 | 0.219 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 6.095150e-01 | 0.215 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 6.095150e-01 | 0.215 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 6.095150e-01 | 0.215 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 6.095150e-01 | 0.215 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 6.095150e-01 | 0.215 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 6.096471e-01 | 0.215 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 6.096471e-01 | 0.215 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 6.096471e-01 | 0.215 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 6.096471e-01 | 0.215 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 6.158901e-01 | 0.210 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 6.158901e-01 | 0.210 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 6.158901e-01 | 0.210 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 6.158901e-01 | 0.210 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 6.158901e-01 | 0.210 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 6.158901e-01 | 0.210 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 6.158901e-01 | 0.210 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 6.174310e-01 | 0.209 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 6.176605e-01 | 0.209 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.197551e-01 | 0.208 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 6.224086e-01 | 0.206 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 6.224086e-01 | 0.206 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 6.224086e-01 | 0.206 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 6.265188e-01 | 0.203 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 6.288026e-01 | 0.201 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 6.288026e-01 | 0.201 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 6.321070e-01 | 0.199 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 6.349875e-01 | 0.197 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 6.409416e-01 | 0.193 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 6.409416e-01 | 0.193 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 6.439301e-01 | 0.191 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 6.466669e-01 | 0.189 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 6.475850e-01 | 0.189 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 6.475850e-01 | 0.189 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 6.475850e-01 | 0.189 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 6.475850e-01 | 0.189 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 6.475850e-01 | 0.189 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 6.475850e-01 | 0.189 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 6.486760e-01 | 0.188 | 0 | 0 |
| Hypusine synthesis from eIF5A-lysine | R-HSA-204626 | 6.510967e-01 | 0.186 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 6.510967e-01 | 0.186 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 6.510967e-01 | 0.186 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 6.510967e-01 | 0.186 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 6.510967e-01 | 0.186 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 6.510967e-01 | 0.186 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 6.510967e-01 | 0.186 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 6.510967e-01 | 0.186 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 6.515707e-01 | 0.186 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 6.521738e-01 | 0.186 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 6.552760e-01 | 0.184 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 6.557885e-01 | 0.183 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 6.625880e-01 | 0.179 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.675229e-01 | 0.176 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 6.679225e-01 | 0.175 | 0 | 0 |
| betaKlotho-mediated ligand binding | R-HSA-1307965 | 6.709933e-01 | 0.173 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 6.709933e-01 | 0.173 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 6.709933e-01 | 0.173 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 6.709933e-01 | 0.173 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 6.709933e-01 | 0.173 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 6.709933e-01 | 0.173 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 6.709933e-01 | 0.173 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 6.709933e-01 | 0.173 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 6.709933e-01 | 0.173 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 6.709933e-01 | 0.173 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 6.709933e-01 | 0.173 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 6.709933e-01 | 0.173 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 6.709933e-01 | 0.173 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 6.709933e-01 | 0.173 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 6.709933e-01 | 0.173 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 6.709933e-01 | 0.173 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 6.709933e-01 | 0.173 | 0 | 0 |
| Toxicity of tetanus toxin (tetX) | R-HSA-5250982 | 6.709933e-01 | 0.173 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 6.728137e-01 | 0.172 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 6.792578e-01 | 0.168 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 6.792578e-01 | 0.168 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 6.792578e-01 | 0.168 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 6.792578e-01 | 0.168 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 6.795460e-01 | 0.168 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.795460e-01 | 0.168 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 6.795460e-01 | 0.168 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 6.812740e-01 | 0.167 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.813860e-01 | 0.167 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 6.829373e-01 | 0.166 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 6.829373e-01 | 0.166 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 6.829373e-01 | 0.166 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.829373e-01 | 0.166 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 6.829373e-01 | 0.166 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 6.829373e-01 | 0.166 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 6.854083e-01 | 0.164 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 6.854083e-01 | 0.164 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 6.884031e-01 | 0.162 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 6.934599e-01 | 0.159 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 6.934599e-01 | 0.159 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 6.940453e-01 | 0.159 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 6.948672e-01 | 0.158 | 0 | 0 |
| Disease | R-HSA-1643685 | 7.029134e-01 | 0.153 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 7.045882e-01 | 0.152 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 7.054313e-01 | 0.152 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 7.054313e-01 | 0.152 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 7.054313e-01 | 0.152 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 7.054313e-01 | 0.152 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 7.080837e-01 | 0.150 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 7.082773e-01 | 0.150 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 7.084668e-01 | 0.150 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 7.084668e-01 | 0.150 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 7.084668e-01 | 0.150 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 7.155740e-01 | 0.145 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 7.155740e-01 | 0.145 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 7.155740e-01 | 0.145 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 7.155740e-01 | 0.145 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 7.155740e-01 | 0.145 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 7.155740e-01 | 0.145 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 7.155740e-01 | 0.145 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 7.155740e-01 | 0.145 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 7.177754e-01 | 0.144 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 7.181209e-01 | 0.144 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 7.262618e-01 | 0.139 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 7.262892e-01 | 0.139 | 0 | 0 |
| FGFR1c and Klotho ligand binding and activation | R-HSA-190374 | 7.266485e-01 | 0.139 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 7.266485e-01 | 0.139 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 7.266485e-01 | 0.139 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 7.266485e-01 | 0.139 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 7.266485e-01 | 0.139 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 7.266485e-01 | 0.139 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 7.266485e-01 | 0.139 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 7.266485e-01 | 0.139 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 7.266485e-01 | 0.139 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 7.266485e-01 | 0.139 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 7.266485e-01 | 0.139 | 0 | 0 |
| Activation of AMPA receptors | R-HSA-399710 | 7.266485e-01 | 0.139 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 7.266485e-01 | 0.139 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 7.266485e-01 | 0.139 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 7.266485e-01 | 0.139 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 7.266485e-01 | 0.139 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 7.269462e-01 | 0.138 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 7.300741e-01 | 0.137 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 7.300741e-01 | 0.137 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 7.300741e-01 | 0.137 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 7.300741e-01 | 0.137 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 7.300741e-01 | 0.137 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 7.314781e-01 | 0.136 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 7.314781e-01 | 0.136 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 7.314781e-01 | 0.136 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 7.314781e-01 | 0.136 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 7.314781e-01 | 0.136 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 7.314781e-01 | 0.136 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 7.314781e-01 | 0.136 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 7.314781e-01 | 0.136 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.314781e-01 | 0.136 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 7.314781e-01 | 0.136 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 7.314781e-01 | 0.136 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 7.314781e-01 | 0.136 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 7.314781e-01 | 0.136 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 7.314781e-01 | 0.136 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 7.354362e-01 | 0.133 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 7.449791e-01 | 0.128 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 7.455449e-01 | 0.128 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 7.455449e-01 | 0.128 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 7.455449e-01 | 0.128 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 7.464639e-01 | 0.127 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 7.488869e-01 | 0.126 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 7.531878e-01 | 0.123 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.593518e-01 | 0.120 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.604783e-01 | 0.119 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 7.604783e-01 | 0.119 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.604783e-01 | 0.119 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 7.604783e-01 | 0.119 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 7.613548e-01 | 0.118 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 7.629818e-01 | 0.117 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 7.633756e-01 | 0.117 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 7.654088e-01 | 0.116 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 7.654088e-01 | 0.116 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 7.654088e-01 | 0.116 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 7.654088e-01 | 0.116 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 7.654088e-01 | 0.116 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 7.654088e-01 | 0.116 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 7.691450e-01 | 0.114 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 7.691450e-01 | 0.114 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 7.691450e-01 | 0.114 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 7.691450e-01 | 0.114 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 7.728917e-01 | 0.112 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 7.728917e-01 | 0.112 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 7.728917e-01 | 0.112 | 0 | 0 |
| Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS) | R-HSA-5619063 | 7.728917e-01 | 0.112 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 7.728917e-01 | 0.112 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 7.728917e-01 | 0.112 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 7.728917e-01 | 0.112 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 7.728917e-01 | 0.112 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 7.728917e-01 | 0.112 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 7.728917e-01 | 0.112 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 7.728917e-01 | 0.112 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 7.728917e-01 | 0.112 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 7.728917e-01 | 0.112 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 7.728917e-01 | 0.112 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 7.728917e-01 | 0.112 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 7.728917e-01 | 0.112 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 7.728917e-01 | 0.112 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 7.728917e-01 | 0.112 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 7.728917e-01 | 0.112 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 7.728917e-01 | 0.112 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 7.728917e-01 | 0.112 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 7.728917e-01 | 0.112 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 7.728917e-01 | 0.112 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 7.729364e-01 | 0.112 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 7.729364e-01 | 0.112 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 7.729364e-01 | 0.112 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 7.729364e-01 | 0.112 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 7.782113e-01 | 0.109 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 7.835883e-01 | 0.106 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 7.881593e-01 | 0.103 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 7.902308e-01 | 0.102 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 7.903154e-01 | 0.102 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 7.912179e-01 | 0.102 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 7.940740e-01 | 0.100 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 7.949106e-01 | 0.100 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 7.949106e-01 | 0.100 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 7.955469e-01 | 0.099 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 7.955469e-01 | 0.099 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 7.955469e-01 | 0.099 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 7.955469e-01 | 0.099 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 7.955469e-01 | 0.099 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 7.955469e-01 | 0.099 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 7.955469e-01 | 0.099 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 7.955469e-01 | 0.099 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 7.955469e-01 | 0.099 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 7.978620e-01 | 0.098 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 8.019869e-01 | 0.096 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.036039e-01 | 0.095 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 8.036618e-01 | 0.095 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.049786e-01 | 0.094 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 8.049786e-01 | 0.094 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 8.049786e-01 | 0.094 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 8.059541e-01 | 0.094 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 8.064313e-01 | 0.093 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 8.064313e-01 | 0.093 | 0 | 0 |
| Metabolism of ingested MeSeO2H into MeSeH | R-HSA-5263617 | 8.113140e-01 | 0.091 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 8.113140e-01 | 0.091 | 0 | 0 |
| Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD | R-HSA-9865125 | 8.113140e-01 | 0.091 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 8.113140e-01 | 0.091 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 8.113140e-01 | 0.091 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 8.113140e-01 | 0.091 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 8.113140e-01 | 0.091 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.135926e-01 | 0.090 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 8.164967e-01 | 0.088 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 8.198667e-01 | 0.086 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 8.204538e-01 | 0.086 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 8.204538e-01 | 0.086 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 8.204538e-01 | 0.086 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 8.204538e-01 | 0.086 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 8.204538e-01 | 0.086 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 8.204538e-01 | 0.086 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 8.215719e-01 | 0.085 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 8.222042e-01 | 0.085 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 8.222042e-01 | 0.085 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 8.222042e-01 | 0.085 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 8.245740e-01 | 0.084 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 8.325835e-01 | 0.080 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 8.408559e-01 | 0.075 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 8.425090e-01 | 0.074 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.425090e-01 | 0.074 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 8.425090e-01 | 0.074 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 8.432378e-01 | 0.074 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 8.432378e-01 | 0.074 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 8.432378e-01 | 0.074 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 8.432378e-01 | 0.074 | 0 | 0 |
| Opsins | R-HSA-419771 | 8.432378e-01 | 0.074 | 0 | 0 |
| Reuptake of GABA | R-HSA-888593 | 8.432378e-01 | 0.074 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 8.432378e-01 | 0.074 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 8.432378e-01 | 0.074 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 8.432378e-01 | 0.074 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 8.432378e-01 | 0.074 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 8.432378e-01 | 0.074 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 8.456035e-01 | 0.073 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 8.456957e-01 | 0.073 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.456957e-01 | 0.073 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.456957e-01 | 0.073 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 8.456957e-01 | 0.073 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 8.520518e-01 | 0.070 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.588745e-01 | 0.066 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 8.588745e-01 | 0.066 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 8.592189e-01 | 0.066 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 8.645373e-01 | 0.063 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 8.656637e-01 | 0.063 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 8.663295e-01 | 0.062 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 8.663295e-01 | 0.062 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 8.663295e-01 | 0.062 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 8.663295e-01 | 0.062 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 8.663295e-01 | 0.062 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 8.697619e-01 | 0.061 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 8.697619e-01 | 0.061 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 8.697619e-01 | 0.061 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 8.697619e-01 | 0.061 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 8.697619e-01 | 0.061 | 0 | 0 |
| Fructose biosynthesis | R-HSA-5652227 | 8.697619e-01 | 0.061 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 8.697619e-01 | 0.061 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 8.697619e-01 | 0.061 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 8.697619e-01 | 0.061 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.704852e-01 | 0.060 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.704852e-01 | 0.060 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 8.706477e-01 | 0.060 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 8.706477e-01 | 0.060 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 8.737654e-01 | 0.059 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 8.756957e-01 | 0.058 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 8.756957e-01 | 0.058 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 8.756957e-01 | 0.058 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 8.756957e-01 | 0.058 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 8.793338e-01 | 0.056 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.800913e-01 | 0.055 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.808337e-01 | 0.055 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 8.844000e-01 | 0.053 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 8.844000e-01 | 0.053 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 8.844000e-01 | 0.053 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 8.844000e-01 | 0.053 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 8.860166e-01 | 0.053 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 8.872780e-01 | 0.052 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 8.892705e-01 | 0.051 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 8.892705e-01 | 0.051 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 8.892705e-01 | 0.051 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.892705e-01 | 0.051 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 8.904377e-01 | 0.050 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 8.904377e-01 | 0.050 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 8.904377e-01 | 0.050 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 8.917994e-01 | 0.050 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 8.917994e-01 | 0.050 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 8.917994e-01 | 0.050 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 8.917994e-01 | 0.050 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 8.917994e-01 | 0.050 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 8.917994e-01 | 0.050 | 0 | 0 |
| Expression of NOTCH2NL genes | R-HSA-9911233 | 8.917994e-01 | 0.050 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 8.921296e-01 | 0.050 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 8.934421e-01 | 0.049 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 8.982927e-01 | 0.047 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 8.995090e-01 | 0.046 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.995090e-01 | 0.046 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 9.001837e-01 | 0.046 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 9.001837e-01 | 0.046 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 9.001837e-01 | 0.046 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 9.001837e-01 | 0.046 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.001837e-01 | 0.046 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 9.001837e-01 | 0.046 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 9.001837e-01 | 0.046 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.031177e-01 | 0.044 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.044467e-01 | 0.044 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 9.068927e-01 | 0.042 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.092543e-01 | 0.041 | 0 | 0 |
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | R-HSA-629594 | 9.101090e-01 | 0.041 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 9.101090e-01 | 0.041 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 9.101090e-01 | 0.041 | 0 | 0 |
| Metabolism of serotonin | R-HSA-380612 | 9.101090e-01 | 0.041 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 9.101090e-01 | 0.041 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 9.101090e-01 | 0.041 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 9.101090e-01 | 0.041 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 9.101090e-01 | 0.041 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 9.101090e-01 | 0.041 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 9.101090e-01 | 0.041 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.105535e-01 | 0.041 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.105535e-01 | 0.041 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 9.139369e-01 | 0.039 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 9.139369e-01 | 0.039 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.139369e-01 | 0.039 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 9.139369e-01 | 0.039 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 9.153020e-01 | 0.038 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.153020e-01 | 0.038 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.153020e-01 | 0.038 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.205039e-01 | 0.036 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 9.205039e-01 | 0.036 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 9.253211e-01 | 0.034 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 9.253211e-01 | 0.034 | 0 | 0 |
| Utilization of Ketone Bodies | R-HSA-77108 | 9.253211e-01 | 0.034 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 9.253211e-01 | 0.034 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 9.253211e-01 | 0.034 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 9.253211e-01 | 0.034 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.257008e-01 | 0.034 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.257008e-01 | 0.034 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.257008e-01 | 0.034 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.257008e-01 | 0.034 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 9.257008e-01 | 0.034 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.257008e-01 | 0.034 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.257008e-01 | 0.034 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.257008e-01 | 0.034 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.258949e-01 | 0.033 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 9.258949e-01 | 0.033 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.260351e-01 | 0.033 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.268547e-01 | 0.033 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.295248e-01 | 0.032 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.332595e-01 | 0.030 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.349157e-01 | 0.029 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.349157e-01 | 0.029 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.349157e-01 | 0.029 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.362712e-01 | 0.029 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.362712e-01 | 0.029 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.374752e-01 | 0.028 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 9.379596e-01 | 0.028 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 9.379596e-01 | 0.028 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 9.379596e-01 | 0.028 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 9.379596e-01 | 0.028 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 9.379596e-01 | 0.028 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 9.379596e-01 | 0.028 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 9.379596e-01 | 0.028 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.401150e-01 | 0.027 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.418878e-01 | 0.026 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.430650e-01 | 0.025 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.430650e-01 | 0.025 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.446618e-01 | 0.025 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.446618e-01 | 0.025 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.446618e-01 | 0.025 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 9.452587e-01 | 0.024 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.452587e-01 | 0.024 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.465339e-01 | 0.024 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.466080e-01 | 0.024 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.478290e-01 | 0.023 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.478290e-01 | 0.023 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 9.484598e-01 | 0.023 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 9.502581e-01 | 0.022 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.525145e-01 | 0.021 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 9.530301e-01 | 0.021 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.530301e-01 | 0.021 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 9.530301e-01 | 0.021 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 9.530301e-01 | 0.021 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 9.530301e-01 | 0.021 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.530301e-01 | 0.021 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.530301e-01 | 0.021 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.565964e-01 | 0.019 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.568164e-01 | 0.019 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 9.571833e-01 | 0.019 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 9.571833e-01 | 0.019 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 9.571833e-01 | 0.019 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 9.571833e-01 | 0.019 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 9.571833e-01 | 0.019 | 0 | 0 |
| Postsynaptic nicotinic acetylcholine receptors | R-HSA-622327 | 9.571833e-01 | 0.019 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 9.571833e-01 | 0.019 | 0 | 0 |
| Acetylcholine binding and downstream events | R-HSA-181431 | 9.571833e-01 | 0.019 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.584643e-01 | 0.018 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.597395e-01 | 0.018 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.599149e-01 | 0.018 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.619214e-01 | 0.017 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.619214e-01 | 0.017 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.621706e-01 | 0.017 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.632275e-01 | 0.016 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.639183e-01 | 0.016 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 9.644308e-01 | 0.016 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 9.644308e-01 | 0.016 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 9.644308e-01 | 0.016 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 9.644308e-01 | 0.016 | 0 | 0 |
| Vitamin B2 (riboflavin) metabolism | R-HSA-196843 | 9.644308e-01 | 0.016 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 9.644308e-01 | 0.016 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 9.644308e-01 | 0.016 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 9.644308e-01 | 0.016 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 9.655238e-01 | 0.015 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.655238e-01 | 0.015 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.664614e-01 | 0.015 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.689953e-01 | 0.014 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.690847e-01 | 0.014 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 9.704518e-01 | 0.013 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 9.704518e-01 | 0.013 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 9.704518e-01 | 0.013 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 9.704518e-01 | 0.013 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.704518e-01 | 0.013 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 9.705039e-01 | 0.013 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.705039e-01 | 0.013 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.705039e-01 | 0.013 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.750425e-01 | 0.011 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.751177e-01 | 0.011 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.754539e-01 | 0.011 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 9.754539e-01 | 0.011 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 9.754539e-01 | 0.011 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 9.754539e-01 | 0.011 | 0 | 0 |
| Carnitine synthesis | R-HSA-71262 | 9.754539e-01 | 0.011 | 0 | 0 |
| Mitochondrial Uncoupling | R-HSA-166187 | 9.754539e-01 | 0.011 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.754539e-01 | 0.011 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 9.754539e-01 | 0.011 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.756179e-01 | 0.011 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.766166e-01 | 0.010 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.769798e-01 | 0.010 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.772417e-01 | 0.010 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.784044e-01 | 0.009 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.784643e-01 | 0.009 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 9.796094e-01 | 0.009 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 9.796094e-01 | 0.009 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 9.796094e-01 | 0.009 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 9.796094e-01 | 0.009 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 9.796094e-01 | 0.009 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 9.796094e-01 | 0.009 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.796094e-01 | 0.009 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.800305e-01 | 0.009 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.816199e-01 | 0.008 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.825019e-01 | 0.008 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.825019e-01 | 0.008 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.830617e-01 | 0.007 | 0 | 0 |
| GDP-fucose biosynthesis | R-HSA-6787639 | 9.830617e-01 | 0.007 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 9.830617e-01 | 0.007 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.837780e-01 | 0.007 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 9.843245e-01 | 0.007 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 9.843245e-01 | 0.007 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.843245e-01 | 0.007 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 9.843245e-01 | 0.007 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.843245e-01 | 0.007 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.859296e-01 | 0.006 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.859296e-01 | 0.006 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 9.859296e-01 | 0.006 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.859589e-01 | 0.006 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.859589e-01 | 0.006 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.862102e-01 | 0.006 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.866019e-01 | 0.006 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.868962e-01 | 0.006 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.883120e-01 | 0.005 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.883120e-01 | 0.005 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.883120e-01 | 0.005 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 9.883120e-01 | 0.005 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.886216e-01 | 0.005 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 9.886216e-01 | 0.005 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.889634e-01 | 0.005 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.889634e-01 | 0.005 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.895065e-01 | 0.005 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.897271e-01 | 0.004 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.897271e-01 | 0.004 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 9.902912e-01 | 0.004 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.902912e-01 | 0.004 | 0 | 0 |
| Melanin biosynthesis | R-HSA-5662702 | 9.902912e-01 | 0.004 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.902912e-01 | 0.004 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.902912e-01 | 0.004 | 0 | 0 |
| Synthesis of Ketone Bodies | R-HSA-77111 | 9.902912e-01 | 0.004 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.902912e-01 | 0.004 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.905178e-01 | 0.004 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.912183e-01 | 0.004 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.917613e-01 | 0.004 | 0 | 0 |
| Abacavir metabolism | R-HSA-2161541 | 9.919353e-01 | 0.004 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.919353e-01 | 0.004 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.921819e-01 | 0.003 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.925004e-01 | 0.003 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.926975e-01 | 0.003 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.929956e-01 | 0.003 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.929956e-01 | 0.003 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.932273e-01 | 0.003 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.932273e-01 | 0.003 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.932591e-01 | 0.003 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.933011e-01 | 0.003 | 0 | 0 |
| Androgen biosynthesis | R-HSA-193048 | 9.933011e-01 | 0.003 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.933011e-01 | 0.003 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.940482e-01 | 0.003 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.943074e-01 | 0.002 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.943074e-01 | 0.002 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.943394e-01 | 0.002 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.944356e-01 | 0.002 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.944356e-01 | 0.002 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.944356e-01 | 0.002 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.949453e-01 | 0.002 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.949453e-01 | 0.002 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.949990e-01 | 0.002 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.950733e-01 | 0.002 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.953781e-01 | 0.002 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.953781e-01 | 0.002 | 0 | 0 |
| Ketone body metabolism | R-HSA-74182 | 9.953781e-01 | 0.002 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.953781e-01 | 0.002 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.953781e-01 | 0.002 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.953781e-01 | 0.002 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.953781e-01 | 0.002 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.956438e-01 | 0.002 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.957092e-01 | 0.002 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.957092e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.958815e-01 | 0.002 | 0 | 0 |
| CYP2E1 reactions | R-HSA-211999 | 9.961610e-01 | 0.002 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.961610e-01 | 0.002 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.963544e-01 | 0.002 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.963595e-01 | 0.002 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.963595e-01 | 0.002 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.966974e-01 | 0.001 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 9.968113e-01 | 0.001 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.969126e-01 | 0.001 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.971038e-01 | 0.001 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.971492e-01 | 0.001 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.971921e-01 | 0.001 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.973514e-01 | 0.001 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.973514e-01 | 0.001 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.973514e-01 | 0.001 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 9.973828e-01 | 0.001 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.977736e-01 | 0.001 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.977824e-01 | 0.001 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.978001e-01 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.978107e-01 | 0.001 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.980802e-01 | 0.001 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.981217e-01 | 0.001 | 0 | 0 |
| Iron assimilation using enterobactin | R-HSA-9638334 | 9.981728e-01 | 0.001 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.981728e-01 | 0.001 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.983596e-01 | 0.001 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.984097e-01 | 0.001 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.984097e-01 | 0.001 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.984824e-01 | 0.001 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.984824e-01 | 0.001 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.985771e-01 | 0.001 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.985812e-01 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.987300e-01 | 0.001 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.987332e-01 | 0.001 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.988947e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.988947e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.991402e-01 | 0.000 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.992779e-01 | 0.000 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.993118e-01 | 0.000 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.993118e-01 | 0.000 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.993210e-01 | 0.000 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.994003e-01 | 0.000 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.994185e-01 | 0.000 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.995043e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.995233e-01 | 0.000 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 9.995863e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 9.995863e-01 | 0.000 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.996499e-01 | 0.000 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.997147e-01 | 0.000 | 0 | 0 |
| Ubiquinol biosynthesis | R-HSA-2142789 | 9.997147e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.997147e-01 | 0.000 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.997147e-01 | 0.000 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.997147e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.997194e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.997221e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.997369e-01 | 0.000 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.997631e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.997830e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.997897e-01 | 0.000 | 0 | 0 |
| Diseases associated with N-glycosylation of proteins | R-HSA-3781860 | 9.998032e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.998118e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.998370e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.998370e-01 | 0.000 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.998643e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.998760e-01 | 0.000 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.998882e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.998994e-01 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.999018e-01 | 0.000 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.999223e-01 | 0.000 | 0 | 0 |
| Synthesis of very long-chain fatty acyl-CoAs | R-HSA-75876 | 9.999223e-01 | 0.000 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.999355e-01 | 0.000 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.999355e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999379e-01 | 0.000 | 0 | 0 |
| The canonical retinoid cycle in rods (twilight vision) | R-HSA-2453902 | 9.999464e-01 | 0.000 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.999464e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.999466e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.999473e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999483e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.999552e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.999590e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.999620e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.999622e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.999628e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.999630e-01 | 0.000 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.999705e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.999726e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999728e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999784e-01 | 0.000 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.999788e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999822e-01 | 0.000 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.999824e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.999866e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.999866e-01 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.999887e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999908e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.999931e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.999933e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999936e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999952e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.999960e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.999973e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.999980e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999984e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999984e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999988e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.999993e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999993e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999993e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999993e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999993e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999995e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.999998e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999998e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999999e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999999e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 1.000000e+00 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | -0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | -0.000 | 0 | 0 |